ZA200505564B - 4-aminopyrimidine-5-one - Google Patents
4-aminopyrimidine-5-one Download PDFInfo
- Publication number
- ZA200505564B ZA200505564B ZA200505564A ZA200505564A ZA200505564B ZA 200505564 B ZA200505564 B ZA 200505564B ZA 200505564 A ZA200505564 A ZA 200505564A ZA 200505564 A ZA200505564 A ZA 200505564A ZA 200505564 B ZA200505564 B ZA 200505564B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino
- pyrimidin
- ylamino
- methoxy
- piperidin
- Prior art date
Links
- WYPGFVLAEWKLCO-UHFFFAOYSA-N 4-amino-4h-pyrimidin-5-one Chemical compound NC1N=CN=CC1=O WYPGFVLAEWKLCO-UHFFFAOYSA-N 0.000 title description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 270
- 229910052736 halogen Inorganic materials 0.000 claims description 107
- 150000002367 halogens Chemical class 0.000 claims description 106
- 125000003118 aryl group Chemical group 0.000 claims description 81
- 150000001875 compounds Chemical class 0.000 claims description 72
- 125000000623 heterocyclic group Chemical group 0.000 claims description 68
- -1 OR" Chemical group 0.000 claims description 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- 125000006413 ring segment Chemical group 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 229910020008 S(O) Inorganic materials 0.000 claims description 13
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- KIXUFRBQGWSJRO-UHFFFAOYSA-N 1-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 KIXUFRBQGWSJRO-UHFFFAOYSA-N 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- VIIIAPSCTBJJNE-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 VIIIAPSCTBJJNE-UHFFFAOYSA-N 0.000 claims description 3
- DPZUJPXVAPZHTQ-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(5-fluoro-2-methoxy-4-methylphenyl)methanone Chemical compound COC1=CC(C)=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 DPZUJPXVAPZHTQ-UHFFFAOYSA-N 0.000 claims description 3
- WDMMNQHJVMDGJQ-UHFFFAOYSA-N [4-amino-2-[[1-(3-chloropropylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCCl)CC1 WDMMNQHJVMDGJQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- RJLDPRWUPPRFLJ-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2,6-difluoro-3-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC=C(F)C(C(=O)C=2C(=NC(NC3CCN(CC3)C(C)=O)=NC=2)N)=C1F RJLDPRWUPPRFLJ-UHFFFAOYSA-N 0.000 claims description 2
- MJJURVOMZQKDBC-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2,6-dimethoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC=CC(OC)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 MJJURVOMZQKDBC-UHFFFAOYSA-N 0.000 claims description 2
- GTUMWQLKDBVXDE-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2-methoxy-5-methylbenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC=C(C)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 GTUMWQLKDBVXDE-UHFFFAOYSA-N 0.000 claims description 2
- UNPAMFCGSKRPGC-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-(diethylamino)propan-1-one Chemical compound C1CN(C(=O)CCN(CC)CC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC UNPAMFCGSKRPGC-UHFFFAOYSA-N 0.000 claims description 2
- HSCHLSHXMZSLHJ-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-methylbutan-1-one Chemical compound COC1=CC=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)CC(C)C)CC1 HSCHLSHXMZSLHJ-UHFFFAOYSA-N 0.000 claims description 2
- YQGOLKAPGJXEGX-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC YQGOLKAPGJXEGX-UHFFFAOYSA-N 0.000 claims description 2
- HRWDCIVZBHCWOU-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 HRWDCIVZBHCWOU-UHFFFAOYSA-N 0.000 claims description 2
- APFFKFCJLZRXMJ-UHFFFAOYSA-N 1-[4-[[4-amino-5-(5-fluoro-2-methoxy-4-methylbenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC(C)=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 APFFKFCJLZRXMJ-UHFFFAOYSA-N 0.000 claims description 2
- CCBBYTWSEZKLPZ-UHFFFAOYSA-N 1-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-(diethylamino)propan-1-one Chemical compound C1CN(C(=O)CCN(CC)CC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC CCBBYTWSEZKLPZ-UHFFFAOYSA-N 0.000 claims description 2
- MVLANSFILWKYMF-UHFFFAOYSA-N 1-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-piperidin-1-ylpropan-1-one Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)CCN2CCCCC2)CC1 MVLANSFILWKYMF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- IUIYCVSWFWKFOP-UHFFFAOYSA-N 4-[[4-amino-5-(2,3-difluoro-6-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-sulfonamide Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(N)(=O)=O)CC1 IUIYCVSWFWKFOP-UHFFFAOYSA-N 0.000 claims description 2
- GIFWLUDQYFWBMB-UHFFFAOYSA-N 4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]-n-ethylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC GIFWLUDQYFWBMB-UHFFFAOYSA-N 0.000 claims description 2
- BUJWVINVXGAHNR-UHFFFAOYSA-N 4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]-n-propylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NCCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC BUJWVINVXGAHNR-UHFFFAOYSA-N 0.000 claims description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 2
- ALKHVWYPHMXSLD-UHFFFAOYSA-N [4-amino-2-(piperidin-4-ylamino)pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCNCC1 ALKHVWYPHMXSLD-UHFFFAOYSA-N 0.000 claims description 2
- PIFCLUGDBBSXER-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-5,6-dihydroxyphenyl)methanone Chemical compound C1CN(S(=O)(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=C(O)C(O)=CC(F)=C1F PIFCLUGDBBSXER-UHFFFAOYSA-N 0.000 claims description 2
- VCTRWEBCRZJBLF-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-hydroxy-5-methoxyphenyl)methanone Chemical compound COC1=CC(F)=C(F)C(C(=O)C=2C(=NC(NC3CCN(CC3)S(C)(=O)=O)=NC=2)N)=C1O VCTRWEBCRZJBLF-UHFFFAOYSA-N 0.000 claims description 2
- UNNOKHXHKNPXBK-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-hydroxyphenyl)methanone Chemical compound C1CN(S(=O)(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=C(O)C=CC(F)=C1F UNNOKHXHKNPXBK-UHFFFAOYSA-N 0.000 claims description 2
- XXQBKANSEMEDRD-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,5-dimethoxyphenyl)methanone Chemical compound COC1=CC=C(OC)C(C(=O)C=2C(=NC(NC3CCN(CC3)S(C)(=O)=O)=NC=2)N)=C1 XXQBKANSEMEDRD-UHFFFAOYSA-N 0.000 claims description 2
- RYDYZSUNWLDOFG-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-ethoxy-3-fluoro-6-methoxyphenyl)methanone Chemical compound CCOC1=C(F)C=CC(OC)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 RYDYZSUNWLDOFG-UHFFFAOYSA-N 0.000 claims description 2
- WJRVIPIXDKUNOB-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-ethyl-5-fluorophenyl)methanone Chemical compound CCC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 WJRVIPIXDKUNOB-UHFFFAOYSA-N 0.000 claims description 2
- TZGPMJHIVPSYBD-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-fluorophenyl)methanone Chemical compound C1CN(S(=O)(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1F TZGPMJHIVPSYBD-UHFFFAOYSA-N 0.000 claims description 2
- RWNJSNYWUAGDGV-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(3,5-difluoro-2-methoxyphenyl)methanone Chemical compound COC1=C(F)C=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 RWNJSNYWUAGDGV-UHFFFAOYSA-N 0.000 claims description 2
- GAKZDWNGSKKFCN-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(3-fluoro-2,6-dimethoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(OC)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 GAKZDWNGSKKFCN-UHFFFAOYSA-N 0.000 claims description 2
- ZNKFHXPLLAHJDI-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(3-fluoro-4-methoxyphenyl)methanone Chemical compound C1=C(F)C(OC)=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 ZNKFHXPLLAHJDI-UHFFFAOYSA-N 0.000 claims description 2
- NPMSZRCLKRSJAI-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(3-fluoro-6-methoxy-2-methylphenyl)methanone Chemical compound COC1=CC=C(F)C(C)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 NPMSZRCLKRSJAI-UHFFFAOYSA-N 0.000 claims description 2
- KUCZTOFSRPKLJU-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(4-chloro-5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC(Cl)=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 KUCZTOFSRPKLJU-UHFFFAOYSA-N 0.000 claims description 2
- DAXFUNOBVQEIPD-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(4-ethoxy-5-fluoro-2-methoxyphenyl)methanone Chemical compound C1=C(F)C(OCC)=CC(OC)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 DAXFUNOBVQEIPD-UHFFFAOYSA-N 0.000 claims description 2
- DUDZGBIGBNJPAI-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 DUDZGBIGBNJPAI-UHFFFAOYSA-N 0.000 claims description 2
- RENMPENBSXRYBF-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-[5-fluoro-2-(trifluoromethyl)phenyl]methanone Chemical compound C1CN(S(=O)(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1C(F)(F)F RENMPENBSXRYBF-UHFFFAOYSA-N 0.000 claims description 2
- WYHDCVFVUQCKMJ-UHFFFAOYSA-N [4-amino-2-[[1-(1-benzothiophen-3-ylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)C=2C3=CC=CC=C3SC=2)CC1 WYHDCVFVUQCKMJ-UHFFFAOYSA-N 0.000 claims description 2
- WFDKVLXJAHDQEF-UHFFFAOYSA-N [4-amino-2-[[1-(3-chloropropylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCCl)CC1 WFDKVLXJAHDQEF-UHFFFAOYSA-N 0.000 claims description 2
- OEIBWASMWUBNET-UHFFFAOYSA-N [4-amino-2-[[1-(4-hydroxybutylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCCO)CC1 OEIBWASMWUBNET-UHFFFAOYSA-N 0.000 claims description 2
- XDNLKIFTXGMIRA-UHFFFAOYSA-N [4-amino-2-[[1-(trifluoromethylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)C(F)(F)F)CC1 XDNLKIFTXGMIRA-UHFFFAOYSA-N 0.000 claims description 2
- QFBGNICJPLDOMR-UHFFFAOYSA-N [4-amino-2-[[1-[3-(2-hydroxypropylamino)propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCNCC(C)O)CC1 QFBGNICJPLDOMR-UHFFFAOYSA-N 0.000 claims description 2
- DVYAJVUTCDZITB-UHFFFAOYSA-N [4-amino-2-[[1-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN2CCN(CCO)CC2)CC1 DVYAJVUTCDZITB-UHFFFAOYSA-N 0.000 claims description 2
- TZXDTDQDRJPLOG-QGZVFWFLSA-N [4-amino-2-[[1-[3-[[(2r)-1-hydroxybutan-2-yl]amino]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound C1CN(S(=O)(=O)CCCN[C@@H](CO)CC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC TZXDTDQDRJPLOG-QGZVFWFLSA-N 0.000 claims description 2
- WKAHCXYGFUYSHY-HNNXBMFYSA-N [4-amino-2-[[1-[3-[[(2s)-1-hydroxypropan-2-yl]amino]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN[C@@H](C)CO)CC1 WKAHCXYGFUYSHY-HNNXBMFYSA-N 0.000 claims description 2
- CGPHHLSJMVEMCB-UHFFFAOYSA-N [4-amino-2-[[1-[4-(4-methylpiperazin-1-yl)butylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCCN2CCN(C)CC2)CC1 CGPHHLSJMVEMCB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims description 2
- GZGRBXHWGKYVRJ-UHFFFAOYSA-N ethyl 4-[[4-amino-5-(2-fluorobenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1F GZGRBXHWGKYVRJ-UHFFFAOYSA-N 0.000 claims description 2
- KKFAWSRIYBKLKA-UHFFFAOYSA-N ethyl 4-[[4-amino-5-(2-methylbenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1C KKFAWSRIYBKLKA-UHFFFAOYSA-N 0.000 claims description 2
- XZGHGEWQIWTMFH-UHFFFAOYSA-N methyl 4-[[4-amino-5-(2,6-difluoro-3-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCC1NC(N=C1N)=NC=C1C(=O)C1=C(F)C=CC(OC)=C1F XZGHGEWQIWTMFH-UHFFFAOYSA-N 0.000 claims description 2
- PRXUBTXZPVGJTN-UHFFFAOYSA-N methyl 4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC PRXUBTXZPVGJTN-UHFFFAOYSA-N 0.000 claims description 2
- DORAUKIUCIASDS-UHFFFAOYSA-N n-[3-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]sulfonylpropyl]methanesulfonamide Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCNS(C)(=O)=O)CC1 DORAUKIUCIASDS-UHFFFAOYSA-N 0.000 claims description 2
- QLGOEHQLSKHKLB-UHFFFAOYSA-N n-[4-[[4-amino-5-(2,3-difluoro-6-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]sulfonylacetamide Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)NC(C)=O)CC1 QLGOEHQLSKHKLB-UHFFFAOYSA-N 0.000 claims description 2
- 238000001783 near-resonance Rayleigh scattering spectroscopy Methods 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- USHPKPPYIYUQJV-UHFFFAOYSA-N propyl 4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC USHPKPPYIYUQJV-UHFFFAOYSA-N 0.000 claims description 2
- RDCWESMEEGWNEQ-UHFFFAOYSA-N propyl 4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC RDCWESMEEGWNEQ-UHFFFAOYSA-N 0.000 claims description 2
- ULBJZIDHABNYKE-UHFFFAOYSA-N tert-butyl 4-[[4-amino-5-(2-fluoro-6-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound COC1=CC=CC(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)OC(C)(C)C)CC1 ULBJZIDHABNYKE-UHFFFAOYSA-N 0.000 claims description 2
- LALAMXZFCQSVPR-UHFFFAOYSA-N tert-butyl 4-[[4-amino-5-(5-fluoro-2-methoxy-4-methylbenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound COC1=CC(C)=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)OC(C)(C)C)CC1 LALAMXZFCQSVPR-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- CVAKVOIENQXVBQ-UHFFFAOYSA-N n-[4-[[4-amino-5-(2,3-difluoro-6-methoxybenzoyl)pyrimidin-2-yl]amino]cyclohexyl]methanesulfonamide Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(NS(C)(=O)=O)CC1 CVAKVOIENQXVBQ-UHFFFAOYSA-N 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- QEYJXOVZSSVWOU-UHFFFAOYSA-N [4-amino-2-[[1-(3-morpholin-4-ylpropylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN2CCOCC2)CC1 QEYJXOVZSSVWOU-UHFFFAOYSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- WYWUYCOEGXENEV-UHFFFAOYSA-N (4-amino-2-ethylsulfanylpyrimidin-5-yl)-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound NC1=NC(SCC)=NC=C1C(=O)C1=C(OC)C=CC(F)=C1F WYWUYCOEGXENEV-UHFFFAOYSA-N 0.000 claims 1
- MFDCPPODFATVOV-UHFFFAOYSA-N (4-amino-2-ethylsulfanylpyrimidin-5-yl)-(2-methoxyphenyl)methanone Chemical compound NC1=NC(SCC)=NC=C1C(=O)C1=CC=CC=C1OC MFDCPPODFATVOV-UHFFFAOYSA-N 0.000 claims 1
- OSCIFGWYKBFJTE-UHFFFAOYSA-N (4-amino-2-ethylsulfanylpyrimidin-5-yl)-(5-fluoro-2-methoxyphenyl)methanone Chemical compound NC1=NC(SCC)=NC=C1C(=O)C1=CC(F)=CC=C1OC OSCIFGWYKBFJTE-UHFFFAOYSA-N 0.000 claims 1
- OWCFHWIZGPPQDW-UHFFFAOYSA-N (4-amino-2-ethylsulfinylpyrimidin-5-yl)-(5-fluoro-2-methoxyphenyl)methanone Chemical compound NC1=NC(S(=O)CC)=NC=C1C(=O)C1=CC(F)=CC=C1OC OWCFHWIZGPPQDW-UHFFFAOYSA-N 0.000 claims 1
- JRNJNYBQQYBCLE-UHFFFAOYSA-N (4-amino-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrimidin-5-yl)(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 JRNJNYBQQYBCLE-UHFFFAOYSA-N 0.000 claims 1
- BIEKWCQOEMKFNS-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2,5-dimethoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC=C(OC)C(C(=O)C=2C(=NC(NC3CCN(CC3)C(C)=O)=NC=2)N)=C1 BIEKWCQOEMKFNS-UHFFFAOYSA-N 0.000 claims 1
- HSGJBUOQIUECJK-UHFFFAOYSA-N 1-[4-[[4-amino-5-(3-methoxypyridine-2-carbonyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC=CN=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 HSGJBUOQIUECJK-UHFFFAOYSA-N 0.000 claims 1
- FLJPPIHOAFBCKH-UHFFFAOYSA-N 1-[4-[[4-amino-5-(3-methylthiophene-2-carbonyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=C(C)C=CS1 FLJPPIHOAFBCKH-UHFFFAOYSA-N 0.000 claims 1
- RQBVAOOZXRCYOZ-UHFFFAOYSA-N 1-[4-[[4-amino-5-(4-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 RQBVAOOZXRCYOZ-UHFFFAOYSA-N 0.000 claims 1
- ZXVYQQOPGJCFKQ-UHFFFAOYSA-N 1-[4-[[4-amino-5-(4-methylbenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=C(C)C=C1 ZXVYQQOPGJCFKQ-UHFFFAOYSA-N 0.000 claims 1
- YDPIKVOJEFVVHH-UHFFFAOYSA-N 3-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]sulfonylpropyl acetate Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCOC(C)=O)CC1 YDPIKVOJEFVVHH-UHFFFAOYSA-N 0.000 claims 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 1
- XKPCTOXMAQFWEX-UHFFFAOYSA-N 4-[[4-amino-5-(2,3-difluoro-6-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carbaldehyde Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C=O)CC1 XKPCTOXMAQFWEX-UHFFFAOYSA-N 0.000 claims 1
- QWIRUBRXAYXRST-UHFFFAOYSA-N 4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]-n-methylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC QWIRUBRXAYXRST-UHFFFAOYSA-N 0.000 claims 1
- WMRACWXPVHBXNS-UHFFFAOYSA-N 4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]-n-[4-(dimethylamino)phenyl]piperidine-1-carboxamide Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)NC=2C=CC(=CC=2)N(C)C)CC1 WMRACWXPVHBXNS-UHFFFAOYSA-N 0.000 claims 1
- LJFHTGIDVOUOTN-UHFFFAOYSA-N 4-amino-2-ethylsulfanyl-n-(methoxymethyl)pyrimidine-5-carboxamide Chemical compound CCSC1=NC=C(C(=O)NCOC)C(N)=N1 LJFHTGIDVOUOTN-UHFFFAOYSA-N 0.000 claims 1
- QNWQUZXWVUANME-UHFFFAOYSA-N 4-amino-n-methoxy-n-methyl-2-methylsulfanylpyrimidine-5-carboxamide Chemical compound CON(C)C(=O)C1=CN=C(SC)N=C1N QNWQUZXWVUANME-UHFFFAOYSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- QEGVQNUSFPTJQQ-HAQNSBGRSA-N COc1ccc(F)c(F)c1C(=O)c1cnc(N[C@H]2CC[C@@H](CC2)NC(=O)CCC(O)=O)nc1N Chemical compound COc1ccc(F)c(F)c1C(=O)c1cnc(N[C@H]2CC[C@@H](CC2)NC(=O)CCC(O)=O)nc1N QEGVQNUSFPTJQQ-HAQNSBGRSA-N 0.000 claims 1
- VBJZIFFZCZAQNI-IYARVYRRSA-N COc1ccc(F)c(F)c1C(=O)c1cnc(N[C@H]2CC[C@@H](CC2)NS(=O)(=O)CCCN2CCN(C)CC2)nc1N Chemical compound COc1ccc(F)c(F)c1C(=O)c1cnc(N[C@H]2CC[C@@H](CC2)NS(=O)(=O)CCCN2CCN(C)CC2)nc1N VBJZIFFZCZAQNI-IYARVYRRSA-N 0.000 claims 1
- ZJHFCMYVCNWAFE-JOCQHMNTSA-N COc1ccc(F)c(F)c1C(=O)c1cnc(N[C@H]2CC[C@@H](CC2)NS(=O)(=O)CCCO)nc1N Chemical compound COc1ccc(F)c(F)c1C(=O)c1cnc(N[C@H]2CC[C@@H](CC2)NS(=O)(=O)CCCO)nc1N ZJHFCMYVCNWAFE-JOCQHMNTSA-N 0.000 claims 1
- VVGPNXXSHISKBU-SHTZXODSSA-N COc1ccc(F)cc1C(=O)c1cnc(N[C@H]2CC[C@@H](CC2)NC(=O)OC(C)(C)C)nc1N Chemical compound COc1ccc(F)cc1C(=O)c1cnc(N[C@H]2CC[C@@H](CC2)NC(=O)OC(C)(C)C)nc1N VVGPNXXSHISKBU-SHTZXODSSA-N 0.000 claims 1
- 101150089916 Miox gene Proteins 0.000 claims 1
- 101150088095 RTM2 gene Chemical group 0.000 claims 1
- SIGCKJAVIAOHEN-UHFFFAOYSA-N [4-amino-2-(piperidin-4-ylamino)pyrimidin-5-yl]-(2-fluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=CC(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCNCC1 SIGCKJAVIAOHEN-UHFFFAOYSA-N 0.000 claims 1
- QVFXVOGOGMAXRY-UHFFFAOYSA-N [4-amino-2-(piperidin-4-ylamino)pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCNCC1 QVFXVOGOGMAXRY-UHFFFAOYSA-N 0.000 claims 1
- OGTMKRSDLAWOJC-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylazetidin-3-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CN(S(C)(=O)=O)C1 OGTMKRSDLAWOJC-UHFFFAOYSA-N 0.000 claims 1
- OSWDSFYYMWLCRH-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-5-hydroxy-6-methoxyphenyl)methanone Chemical compound COC1=C(O)C=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 OSWDSFYYMWLCRH-UHFFFAOYSA-N 0.000 claims 1
- PNORSGBBAIYGIS-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,6-difluoro-3-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(C(=O)C=2C(=NC(NC3CCN(CC3)S(C)(=O)=O)=NC=2)N)=C1F PNORSGBBAIYGIS-UHFFFAOYSA-N 0.000 claims 1
- LLZYWPCRGNCMES-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-fluoro-5-methoxy-4-methylphenyl)methanone Chemical compound C1=C(C)C(OC)=CC(C(=O)C=2C(=NC(NC3CCN(CC3)S(C)(=O)=O)=NC=2)N)=C1F LLZYWPCRGNCMES-UHFFFAOYSA-N 0.000 claims 1
- NWIPTENCWQPQTO-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-fluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=CC(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 NWIPTENCWQPQTO-UHFFFAOYSA-N 0.000 claims 1
- HFZATRIAVXNIOC-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-methoxy-5-methylphenyl)methanone Chemical compound COC1=CC=C(C)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 HFZATRIAVXNIOC-UHFFFAOYSA-N 0.000 claims 1
- SNANURCXNCBFIA-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(3,4,5-trifluoro-2-methoxyphenyl)methanone Chemical compound COC1=C(F)C(F)=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 SNANURCXNCBFIA-UHFFFAOYSA-N 0.000 claims 1
- LCHYKOVLYWLNJH-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(3-methoxypyridin-2-yl)methanone Chemical compound COC1=CC=CN=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 LCHYKOVLYWLNJH-UHFFFAOYSA-N 0.000 claims 1
- URJKJOFBEGLOBC-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(3-methylthiophen-2-yl)methanone Chemical compound C1=CSC(C(=O)C=2C(=NC(NC3CCN(CC3)S(C)(=O)=O)=NC=2)N)=C1C URJKJOFBEGLOBC-UHFFFAOYSA-N 0.000 claims 1
- SGSRQIXCKBBDEJ-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(4-fluorophenyl)methanone Chemical compound C1CN(S(=O)(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=C(F)C=C1 SGSRQIXCKBBDEJ-UHFFFAOYSA-N 0.000 claims 1
- VHMFSVZFQZLSIN-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(5-fluoro-2,4-dimethoxyphenyl)methanone Chemical compound C1=C(F)C(OC)=CC(OC)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 VHMFSVZFQZLSIN-UHFFFAOYSA-N 0.000 claims 1
- CXGFHBJFQBWPBO-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 CXGFHBJFQBWPBO-UHFFFAOYSA-N 0.000 claims 1
- SDCHMPYXIQHAHE-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(5-fluoro-2-methylphenyl)methanone Chemical compound CC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 SDCHMPYXIQHAHE-UHFFFAOYSA-N 0.000 claims 1
- BULJYMRCYCDSKA-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(5-fluoro-2-propan-2-yloxyphenyl)methanone Chemical compound CC(C)OC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 BULJYMRCYCDSKA-UHFFFAOYSA-N 0.000 claims 1
- ANVYHQZGXRCMOQ-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-phenylmethanone Chemical compound C1CN(S(=O)(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1 ANVYHQZGXRCMOQ-UHFFFAOYSA-N 0.000 claims 1
- VSYJHONPRMHORT-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-thiophen-2-ylmethanone Chemical compound C1CN(S(=O)(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CS1 VSYJHONPRMHORT-UHFFFAOYSA-N 0.000 claims 1
- KFNGVRVGNAFTLO-UHFFFAOYSA-N [4-amino-2-[(4-aminocyclohexyl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(N)CC1 KFNGVRVGNAFTLO-UHFFFAOYSA-N 0.000 claims 1
- DWFYFPBSBQDMDR-UHFFFAOYSA-N [4-amino-2-[(4-aminocyclohexyl)amino]pyrimidin-5-yl]-(2-methoxy-5-methylphenyl)methanone Chemical compound COC1=CC=C(C)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(N)CC1 DWFYFPBSBQDMDR-UHFFFAOYSA-N 0.000 claims 1
- YDZOSWOAMCUESY-UHFFFAOYSA-N [4-amino-2-[(4-aminocyclohexyl)amino]pyrimidin-5-yl]-(5-fluoro-2-methoxy-4-methylphenyl)methanone Chemical compound COC1=CC(C)=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(N)CC1 YDZOSWOAMCUESY-UHFFFAOYSA-N 0.000 claims 1
- ATHZNSKPESUNLJ-UHFFFAOYSA-N [4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-5-yl]-(2,6-difluorophenyl)methanone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(N=C1N)=NC=C1C(=O)C1=C(F)C=CC=C1F ATHZNSKPESUNLJ-UHFFFAOYSA-N 0.000 claims 1
- OTZYJTKAIYKEQB-UHFFFAOYSA-N [4-amino-2-[4-(4-propan-2-ylpiperazin-1-yl)anilino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1=CC=C(N2CCN(CC2)C(C)C)C=C1 OTZYJTKAIYKEQB-UHFFFAOYSA-N 0.000 claims 1
- MUEWGEMABGXXQF-UHFFFAOYSA-N [4-amino-2-[[1-(1,3,5-trimethylpyrazol-4-yl)sulfonylpiperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)C2=C(N(C)N=C2C)C)CC1 MUEWGEMABGXXQF-UHFFFAOYSA-N 0.000 claims 1
- MIUOLXYUVMNQNO-UHFFFAOYSA-N [4-amino-2-[[1-(2,5-dimethylthiophen-3-yl)sulfonylpiperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)C2=C(SC(C)=C2)C)CC1 MIUOLXYUVMNQNO-UHFFFAOYSA-N 0.000 claims 1
- SSSRQTQUKLCEOS-UHFFFAOYSA-N [4-amino-2-[[1-(2-methylsulfonylethyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(CCS(C)(=O)=O)CC1 SSSRQTQUKLCEOS-UHFFFAOYSA-N 0.000 claims 1
- IHSDCTNJTZMKTR-UHFFFAOYSA-N [4-amino-2-[[1-(3-hydroxypropylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCO)CC1 IHSDCTNJTZMKTR-UHFFFAOYSA-N 0.000 claims 1
- YEIGXMUBKLHUQD-UHFFFAOYSA-N [4-amino-2-[[1-(4-chlorobutylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCCCl)CC1 YEIGXMUBKLHUQD-UHFFFAOYSA-N 0.000 claims 1
- RZVUQTHIUXQQKB-UHFFFAOYSA-N [4-amino-2-[[1-(4-pyrrolidin-1-ylbutylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCCN2CCCC2)CC1 RZVUQTHIUXQQKB-UHFFFAOYSA-N 0.000 claims 1
- WSGPZHHHUTUZFJ-UHFFFAOYSA-N [4-amino-2-[[1-[3-(4-methylpiperazin-1-yl)propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN2CCN(C)CC2)CC1 WSGPZHHHUTUZFJ-UHFFFAOYSA-N 0.000 claims 1
- GOZIPYFFQQSAGJ-UHFFFAOYSA-N [4-amino-2-[[1-[3-(4-methylpiperazin-1-yl)propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN2CCN(C)CC2)CC1 GOZIPYFFQQSAGJ-UHFFFAOYSA-N 0.000 claims 1
- VRQZUFSTYHBDBA-UHFFFAOYSA-N [4-amino-2-[[1-[3-[2-methoxyethyl(methyl)amino]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound C1CN(S(=O)(=O)CCCN(C)CCOC)CCC1NC(N=C1N)=NC=C1C(=O)C1=C(F)C(F)=CC=C1OC VRQZUFSTYHBDBA-UHFFFAOYSA-N 0.000 claims 1
- ACRYYFAGUHVMGK-UHFFFAOYSA-N [4-amino-2-[[1-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN2CCN(CCO)CC2)CC1 ACRYYFAGUHVMGK-UHFFFAOYSA-N 0.000 claims 1
- NNJHCWIAPCDSKJ-CQSZACIVSA-N [4-amino-2-[[1-[3-[[(2r)-1-hydroxypropan-2-yl]amino]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN[C@H](C)CO)CC1 NNJHCWIAPCDSKJ-CQSZACIVSA-N 0.000 claims 1
- WKAHCXYGFUYSHY-OAHLLOKOSA-N [4-amino-2-[[1-[3-[[(2r)-1-hydroxypropan-2-yl]amino]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN[C@H](C)CO)CC1 WKAHCXYGFUYSHY-OAHLLOKOSA-N 0.000 claims 1
- NNJHCWIAPCDSKJ-AWEZNQCLSA-N [4-amino-2-[[1-[3-[[(2s)-1-hydroxypropan-2-yl]amino]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN[C@@H](C)CO)CC1 NNJHCWIAPCDSKJ-AWEZNQCLSA-N 0.000 claims 1
- RTBWMMSSDXTHKS-UHFFFAOYSA-N [4-amino-2-[[1-[4-(2-hydroxypropylamino)butylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCCNCC(C)O)CC1 RTBWMMSSDXTHKS-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 claims 1
- WRHRVUMPLKRBNL-UHFFFAOYSA-N ethyl 4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC WRHRVUMPLKRBNL-UHFFFAOYSA-N 0.000 claims 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- SRJGOXPJILONEP-UHFFFAOYSA-N methyl 4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC SRJGOXPJILONEP-UHFFFAOYSA-N 0.000 claims 1
- FPGMIEHZKLHZTF-UHFFFAOYSA-N n-(4-aminocyclohexyl)ethanesulfonamide Chemical compound CCS(=O)(=O)NC1CCC(N)CC1 FPGMIEHZKLHZTF-UHFFFAOYSA-N 0.000 claims 1
- YWXJLSMUIUQROI-UHFFFAOYSA-N n-[4-[[4-amino-5-(2-methoxy-5-methylbenzoyl)pyrimidin-2-yl]amino]cyclohexyl]acetamide Chemical compound COC1=CC=C(C)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(NC(C)=O)CC1 YWXJLSMUIUQROI-UHFFFAOYSA-N 0.000 claims 1
- WWJAMJCIIURONO-UHFFFAOYSA-N n-[4-[[4-amino-5-(2-methoxy-5-methylbenzoyl)pyrimidin-2-yl]amino]cyclohexyl]methanesulfonamide Chemical compound COC1=CC=C(C)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(NS(C)(=O)=O)CC1 WWJAMJCIIURONO-UHFFFAOYSA-N 0.000 claims 1
- VGBJVAUEHUGJQH-UHFFFAOYSA-N n-[4-[[4-amino-5-(5-fluoro-2-methoxy-4-methylbenzoyl)pyrimidin-2-yl]amino]cyclohexyl]acetamide Chemical compound COC1=CC(C)=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(NC(C)=O)CC1 VGBJVAUEHUGJQH-UHFFFAOYSA-N 0.000 claims 1
- RAJIRDCBWREJPJ-UHFFFAOYSA-N n-[4-[[4-amino-5-(5-fluoro-2-methoxy-4-methylbenzoyl)pyrimidin-2-yl]amino]cyclohexyl]methanesulfonamide Chemical compound COC1=CC(C)=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(NS(C)(=O)=O)CC1 RAJIRDCBWREJPJ-UHFFFAOYSA-N 0.000 claims 1
- RPRRCIXMEFVGFY-UHFFFAOYSA-N n-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]cyclohexyl]ethanesulfonamide Chemical compound C1CC(NS(=O)(=O)CC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC RPRRCIXMEFVGFY-UHFFFAOYSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- IBYOHBLSLAIBQK-UHFFFAOYSA-N propan-2-yl n-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]cyclohexyl]carbamate Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(NC(=O)OC(C)C)CC1 IBYOHBLSLAIBQK-UHFFFAOYSA-N 0.000 claims 1
- WJZOMLALDHFDRV-UHFFFAOYSA-N tert-butyl n-[4-[[4-amino-5-(2-methoxy-5-methylbenzoyl)pyrimidin-2-yl]amino]cyclohexyl]carbamate Chemical compound COC1=CC=C(C)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(NC(=O)OC(C)(C)C)CC1 WJZOMLALDHFDRV-UHFFFAOYSA-N 0.000 claims 1
- PHLHUGHJOMVLOL-UHFFFAOYSA-N tert-butyl n-[4-[[4-amino-5-(5-fluoro-2-methoxy-4-methylbenzoyl)pyrimidin-2-yl]amino]cyclohexyl]carbamate Chemical compound COC1=CC(C)=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCC(NC(=O)OC(C)(C)C)CC1 PHLHUGHJOMVLOL-UHFFFAOYSA-N 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 12
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 102000003910 Cyclin D Human genes 0.000 description 10
- 108090000259 Cyclin D Proteins 0.000 description 10
- 101150012716 CDK1 gene Proteins 0.000 description 9
- 102000016736 Cyclin Human genes 0.000 description 9
- 108050006400 Cyclin Proteins 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 8
- 101150073031 cdk2 gene Proteins 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000018199 S phase Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000003909 Cyclin E Human genes 0.000 description 4
- 108090000257 Cyclin E Proteins 0.000 description 4
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091007914 CDKs Proteins 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 229940124783 FAK inhibitor Drugs 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 description 3
- 230000006369 cell cycle progression Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- QZTWUDDGLIDXSE-UHFFFAOYSA-N 9-hydroxyellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 QZTWUDDGLIDXSE-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000002554 Cyclin A Human genes 0.000 description 2
- 108010068192 Cyclin A Proteins 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LAGVJEJQNCPFOS-UHFFFAOYSA-N [4-amino-2-[(3-hydroxy-1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1C(O)CN(S(C)(=O)=O)CC1 LAGVJEJQNCPFOS-UHFFFAOYSA-N 0.000 description 2
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000021953 cytokinesis Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- SOCAXRLFGRNEPK-IFZYUDKTSA-N (1r,3s,5r)-2-n-[1-carbamoyl-5-(cyanomethoxy)indol-3-yl]-3-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)NC1=CN(C2=CC=C(OCC#N)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F SOCAXRLFGRNEPK-IFZYUDKTSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- WKXCZMFWXZRMEZ-UHFFFAOYSA-N 1,3-thiazole-2,4-diamine Chemical class NC1=CSC(N)=N1 WKXCZMFWXZRMEZ-UHFFFAOYSA-N 0.000 description 1
- PRISJZMIQULAOH-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2,3,4-trifluoro-6-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC(F)=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 PRISJZMIQULAOH-UHFFFAOYSA-N 0.000 description 1
- GIJQUXUEVNQNNA-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2,3-difluoro-6-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 GIJQUXUEVNQNNA-UHFFFAOYSA-N 0.000 description 1
- OBDPIVSOXGXWQB-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2-ethoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound CCOC1=CC=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(C)=O)CC1 OBDPIVSOXGXWQB-UHFFFAOYSA-N 0.000 description 1
- QFHVRLUDWHWUIM-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2-fluoro-6-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]-2,2,2-trifluoroethanone Chemical compound COC1=CC=CC(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)C(F)(F)F)CC1 QFHVRLUDWHWUIM-UHFFFAOYSA-N 0.000 description 1
- KVAMJHHQKPHBKK-UHFFFAOYSA-N 1-[4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]propan-1-one Chemical compound C1CN(C(=O)CC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC KVAMJHHQKPHBKK-UHFFFAOYSA-N 0.000 description 1
- MFMUZOLZZNULHQ-UHFFFAOYSA-N 1-[4-[[4-amino-5-(4-chlorobenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=C(Cl)C=C1 MFMUZOLZZNULHQ-UHFFFAOYSA-N 0.000 description 1
- NDSGBJXAWDNRFO-UHFFFAOYSA-N 1-[4-[[4-amino-5-(4-fluorobenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=C(F)C=C1 NDSGBJXAWDNRFO-UHFFFAOYSA-N 0.000 description 1
- MLMWWSSAARRRSO-UHFFFAOYSA-N 1-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(diethylamino)ethanone Chemical compound C1CN(C(=O)CN(CC)CC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC MLMWWSSAARRRSO-UHFFFAOYSA-N 0.000 description 1
- AXGWVOXHGXAJCW-UHFFFAOYSA-N 1-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-(dimethylamino)ethanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)CN(C)C)CC1 AXGWVOXHGXAJCW-UHFFFAOYSA-N 0.000 description 1
- BNULMOQBHYCWLT-UHFFFAOYSA-N 1-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-morpholin-4-ylethanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)CN2CCOCC2)CC1 BNULMOQBHYCWLT-UHFFFAOYSA-N 0.000 description 1
- JCIDRADQGFNKRQ-UHFFFAOYSA-N 1-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-(dimethylamino)propan-1-one Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)CCN(C)C)CC1 JCIDRADQGFNKRQ-UHFFFAOYSA-N 0.000 description 1
- ROMZBSDIEHRQPF-UHFFFAOYSA-N 1-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC ROMZBSDIEHRQPF-UHFFFAOYSA-N 0.000 description 1
- VWXIHLCLIOQWRA-UHFFFAOYSA-N 1h-pteridin-2-one Chemical class N1=CC=NC2=NC(O)=NC=C21 VWXIHLCLIOQWRA-UHFFFAOYSA-N 0.000 description 1
- QHPNMVKFLGCBPM-UHFFFAOYSA-N 2-methylpropyl 4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound COC1=CC=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)OCC(C)C)CC1 QHPNMVKFLGCBPM-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- RYEDAYLGISJMIS-UHFFFAOYSA-N 4-[[4-amino-5-(2,3-difluoro-6-methoxybenzoyl)pyrimidin-2-yl]amino]-1-methylsulfonylpiperidin-3-one Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1C(=O)CN(S(C)(=O)=O)CC1 RYEDAYLGISJMIS-UHFFFAOYSA-N 0.000 description 1
- GSGGJHHXLHRLKS-UHFFFAOYSA-N 4-[[4-amino-5-(2-methoxybenzoyl)pyrimidin-2-yl]amino]-n,n-dimethylpiperidine-1-carboxamide Chemical compound COC1=CC=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(C(=O)N(C)C)CC1 GSGGJHHXLHRLKS-UHFFFAOYSA-N 0.000 description 1
- XAVHSVWAOYBLNU-UHFFFAOYSA-N 4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]-n,n-dimethylpiperidine-1-sulfonamide Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)N(C)C)CC1 XAVHSVWAOYBLNU-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical class [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 108010058545 Cyclin D3 Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 1
- 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 description 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 102100026379 Neurofibromin Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229910019567 Re Re Inorganic materials 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- ZJMXSDPJDCXSAG-UHFFFAOYSA-N [4-amino-2-(piperidin-4-ylamino)pyrimidin-5-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCNCC1 ZJMXSDPJDCXSAG-UHFFFAOYSA-N 0.000 description 1
- FLUFOPBQYKZELF-UHFFFAOYSA-N [4-amino-2-[(1-ethylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-fluorophenyl)methanone Chemical compound C1CN(S(=O)(=O)CC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1F FLUFOPBQYKZELF-UHFFFAOYSA-N 0.000 description 1
- CLKJPEPFYDJWOV-UHFFFAOYSA-N [4-amino-2-[(1-ethylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-methoxyphenyl)methanone Chemical compound C1CN(S(=O)(=O)CC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC CLKJPEPFYDJWOV-UHFFFAOYSA-N 0.000 description 1
- JWEAHVKNTBJGAW-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-ethoxy-5-fluorophenyl)methanone Chemical compound CCOC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 JWEAHVKNTBJGAW-UHFFFAOYSA-N 0.000 description 1
- KBJGZYXROHJYJC-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(4-chlorophenyl)methanone Chemical compound C1CN(S(=O)(=O)C)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=C(Cl)C=C1 KBJGZYXROHJYJC-UHFFFAOYSA-N 0.000 description 1
- WNSPAJBLOHMSHF-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 WNSPAJBLOHMSHF-UHFFFAOYSA-N 0.000 description 1
- WHVSULGUTSFAHY-UHFFFAOYSA-N [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-[2-methoxy-4-(trifluoromethyl)phenyl]methanone Chemical compound COC1=CC(C(F)(F)F)=CC=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 WHVSULGUTSFAHY-UHFFFAOYSA-N 0.000 description 1
- KHUMZAIBBGPTAA-UHFFFAOYSA-N [4-amino-2-[(1-propylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2-methoxyphenyl)methanone Chemical compound C1CN(S(=O)(=O)CCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC=CC=C1OC KHUMZAIBBGPTAA-UHFFFAOYSA-N 0.000 description 1
- YCHFZJDJQVRURP-UHFFFAOYSA-N [4-amino-2-[(1-thiophen-3-ylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)C2=CSC=C2)CC1 YCHFZJDJQVRURP-UHFFFAOYSA-N 0.000 description 1
- WUQMBLCOJJIUGZ-UHFFFAOYSA-N [4-amino-2-[[1-(3-hydroxypropylsulfonyl)piperidin-4-yl]amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCO)CC1 WUQMBLCOJJIUGZ-UHFFFAOYSA-N 0.000 description 1
- SJTPYAGWOWGOBE-UHFFFAOYSA-N [4-amino-2-[[1-[3-(1,5-dihydroxypentan-3-ylamino)propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCNC(CCO)CCO)CC1 SJTPYAGWOWGOBE-UHFFFAOYSA-N 0.000 description 1
- FXEULMLEXPNSIX-UHFFFAOYSA-N [4-amino-2-[[1-[3-(1-methoxypropan-2-ylamino)propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound C1CN(S(=O)(=O)CCCNC(C)COC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC FXEULMLEXPNSIX-UHFFFAOYSA-N 0.000 description 1
- PLRGOGXSXSBKQT-UHFFFAOYSA-N [4-amino-2-[[1-[3-[2-methoxyethyl(methyl)amino]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound C1CN(S(=O)(=O)CCCN(C)CCOC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC PLRGOGXSXSBKQT-UHFFFAOYSA-N 0.000 description 1
- TXDYKMRNARWETA-NRFANRHFSA-N [4-amino-2-[[1-[3-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]propylsulfonyl]piperidin-4-yl]amino]pyrimidin-5-yl]-(5-fluoro-2-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(=O)(=O)CCCN[C@@H](CO)C(C)C)CC1 TXDYKMRNARWETA-NRFANRHFSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical class [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- KIKUKVHRVNYPKR-UHFFFAOYSA-N ethyl 4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(N=C1N)=NC=C1C(=O)C1=CC(F)=CC=C1OC KIKUKVHRVNYPKR-UHFFFAOYSA-N 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- PWUOOJVYZQILBG-UHFFFAOYSA-N fascaplysine Chemical compound [Cl-].C1=CC=C2C3=CC=[N+]4C5=CC=CC=C5C(=O)C4=C3NC2=C1 PWUOOJVYZQILBG-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical class C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 description 1
- 229960005544 indolocarbazole Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- RCRXKYYHHOHHKM-UHFFFAOYSA-N methyl 3-[4-[[4-amino-5-(5-fluoro-2-methoxybenzoyl)pyrimidin-2-yl]amino]piperidin-1-yl]sulfonylthiophene-2-carboxylate Chemical compound S1C=CC(S(=O)(=O)N2CCC(CC2)NC=2N=C(N)C(C(=O)C=3C(=CC=C(F)C=3)OC)=CN=2)=C1C(=O)OC RCRXKYYHHOHHKM-UHFFFAOYSA-N 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- VFBILHPIHUPBPZ-UHFFFAOYSA-N n-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide Chemical compound CCOC1=CC=CC=C1C(=O)NCC1=COC(C=2C=C(OC(C)C)C(OC(F)F)=CC=2)=N1 VFBILHPIHUPBPZ-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108700042657 p16 Genes Proteins 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000008518 pyridopyrimidines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
-1- SE
N y 4-Aminopyrimidine-5-one
The present invention relates to novel 4-aminopyrimidine-5-one derivatives of the formula
NH, O
NE R2
M 2 i) N 1
R LL wherein 5s R' isselected from the group consisting of heterocycle and lower alkyl-heterocycle, wherein the heterocycle moiety in both instances optionally may be substituted by up to four substituents independently selected from
H, lower alkyl, : lower alkyl substituted by oxo, OR"?, CO,R'%, NRR®, S(O),RY or
C(O)NRR’,
COR,
CORY, a
CORY, :
C(O)NRPR™,
S(O)aR", 0X0, . OR", or
NR°R%; ’ aryl; aryl substituted by
H,
-2- CL © -S(0)wR”, NR°RS, carbonyl, carbonyl substituted by lower alkyl, OR? or NR’R®, } 5 lower alkyl, : : lower alkyl substituted by OR! or NR°RS,
OR®, or
Halogen; cycloalkyl; cycloalkyl substituted by OR’,NR°R® or $(O)aR" ; lower alkyl; and lower alkyl substituted by
NR’RS,
NR!'SOR",
COzR",
S(0)aR", heterocycle, heterocycle substituted by lower alkyl,
CO,R" or
SOR", heteroaryl, heteroaryl substituted by lower alkyl,
COR", or : SOR”, aryl, and aryl substituted by : lower alkyl, halogen,
NR°R’,
COR" or
COR};
-3- SS
R? is selected from the group consisting of aryl, heteroaryl, cycloalkyl and heterocycle, wherein each may be substituted by up ) to four substituents independently selected from the group consisting of lower alkyl, ’ 5 lower alkyl substituted by halogen or OR", halogen,
OR"
NO,
CN,
NR’RS,
S(0),-R’, and
SO,-NR'*RY;
R® and R® are each independently selected from the group consisting of lower alkyl; lower alkyl substituted by oxo, CO;R'?, OR'2, NR" R™, C(O)NR"R** , SOR",
NSO,R'"?, heteroaryl, heterocycle, or heterocycle substituted by oxo; cycloalkyl; cycloalkyl substituted by CO.R'Z, ORY, NRPR'*, C(O)NR"R™ or SOR aryl aryl substituted by NR¥R', OR'?, COR", C(O)NR"R' , SO,R", halogen, lower : alkyl, or lower alkyl substituted by halogen, OR", oxo, CO:R'%, C(O)NR"R™ or
NRPPR'® 50:R"; : 25 COR"
COR'* and
OR"
Ro. ©) ~ op AO
- or alternatively, -NR°R® can form a ring having 3 to 7 ring atoms, said ring optionally including one or more additional N or O ring atoms or the group SO,, and optionally being substituted by OH, oxo, NR'’R", lower alkyl and lower alkyl substituted by OR'%
R’ is selected from the group consisting of
H; lower alkyl; lower alkyl substituted by OR'?, CO,R'%, NR’RS, or C(O)NRR® i halogen; 0X0; Co aryl; aryl substituted by up to three substituents independently selected from lower alkyl, halogen and NR’R® cycloalkyl; cycloalkyl substituted by OH, oxo, or NH, :
SO,R' and
COR";
R® is selected from the group consisting of :
H; h lower alkyl; lower alkyl substituted by NR’R% . heterocycle; and heterocycle substituted by lower alkyl, COR"? or SOR:
R’ is selected from the group consisting of
H; and lower alkyl; - 25° RY is selected from the group consisting of
-5- oo oo : : lower alkyl; aryl; and aryl substituted by halogen or NR’R®
R" is selected from the group consisting of
H; lower alkyl; and lower alkyl substituted by oxo or halogen;
R"? is selected from the group consisting of
H; lower alkyl; and lower alkyl substituted by NR’R® or OR";
R"’ and R" are each independently selected from the group consisting of o 1; lower alkyl; So lower alkyl substituted by CO,R'?, OR'?, NR’R®, C(O)NR’R?, SO,R!®, NSO.R'?, heteroaryl, heterocycle, or heterocycle substituted by oxo; cycloalkyl; cycloalkyl substituted by CO,R'?, OR'?, NR’RS, C(O)NR’R® or SO,R'%; aryl; aryl substituted by NR’R®, OR, CO,R'?, CONRR®, SO,R"’, halogen, lower alkyl, and lower alkyl substituted by halogen, OR'2, oxo, CO.R'?, C(O)NR’R® or NR°R®
SO.RY;
CO-R'%
COR'% and :
OR?
R10. | _o or alternatively, NRUR can form a ring having 3 to 7 ring atoms, said ring optionally ] including one or more additional N or O ring atoms and optionally being substituted by
OH, oxo, NR’R®, lower alkyl and lower alkyl substituted by. OR"
R'is selected from the group consisting of : aryl;
PCT/EP2004/000971 aryl substituted by the group halogen, CO,R'?, SO,R'%, COR'?, lower alkyl and lower alkyl substituted by halogen, OR'?, oxo, CO,R'?, C(O)NR’R® or NR’R; heteroaryl; heteroaryl substituted by the group halogen, CO,R'?, SOR", COR, lower alkyl and lower alkyl substituted by halogen, OR'2, oxo, CO;R'?, C(O)NR’R® or NR°R®;
NRR%; lower alkyl; lower alkyl substituted by halogen, OR", oxo, COR", C(O)NR°R® or NR°R%; heterocycle, and heterocycle substituted by the group CO,R", COR", SO,R', COR" lower alkyl,
C(O)NR’R®or NR’R’;
R'® and RY are each independently selected from the group consisting of
H; and lower alkyl; or, alternatively, the group —-NR'RY can form a ring having 3 to 7 ring atoms, said ring optionally including one or more additional N or O ring atoms and optionally being substituted by lower alkyl, OH, oxo and NH; and n 1s0,lor2; or the pharmaceutically acceptable salts or esters thereof.
These compounds inhibit cydin-dependent kinases, most particularly cyclin- dependent kinase 4 (Cdk4). Thus, compounds of formula I and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful, inter alia, in the treatment or control of cancer, in particular solid tumors. This invention also relates to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Finally, this invention is also directed to novel intermediate compounds useful in the preparation of the novel diaminopyrimidines herein disclosed.
Uncontrolled cell proliferation is the hallmark of cancer. Cancerous tumor cells typically have some form of damage to the genes that directly or indirectly regulate the cell-division cycle.
AMENDED SHEET
) The progression of cells through the various phases of the cell cycle is regulated bya series of multienzyme complexes consisting of a regulatory protein, a cyclin, and a kinase.
These kinases are called cyclin-dependent kinases (Cdks). The Cdks are expressed ’ throughout the cell cycle, while the levels of the cyclins vary depending on the stage of the cell cycle. ) :
The four primary phases of cell cycle control are generally describes as Gy, S, Go, and M. Some essential enzymes for cell cycle control appear to be cyclin D/Cdk4, cyclin
D/Cdks, cyclin E/Cdk2, cyclin A/Cdk2, and cyclin B/Cdk1 (also known as Cdc2/cyclin
B). Cyclin D/Cdk4, cyclin D/Cdk6, and cyclin E/Cdk?2 control passage through the G;- 10 ., phase and the G;- to S-phase transition by phosphorylation of the retinoblastoma phosphoprotein, pRb. Cyclin A/Cdk2 regulates passage through the S-phase, and cyclin
B/Cdk1 controls the G, checkpoint and regulates entry into M (mitosis) phase.
The cell cycle progression is regulated by Cdk1 (cdc2) and Cdk2 beyond early G, when cells are committed to cytokinesis. Therefore, drug inhibition of these Cdks is ~ 15 likely not only to arrest cell proliferation, but also to trigger apoptotic cell death. Once the cells pass the G, restriction point and are committed to$ phase, they become independent of growth factor stimulation for continued cell cycle progression.
Following completion of DNA replication, cells enter the G; phase of the cell cycle in preparation for M phase and cytokinesis. Cdk1 has been shown to regulate passage of cells through these later phases of the cell cycle in association with both cyclins A and B.
Complete activation of Cdk1 requires both cyclin binding and specific phosphorylation (Morgan, D. O., De Bondt, H. L., Curr. Opin. Cell. Biol. 1994, 6, 239-246). Once activated, Cdk1/cyclin complexes prepare the cell for division during M phase.
The transition from G; phase into S phase as stated above is regulated by the complex of Cdk4 with cyclin D and Cdk2.with cyclin E. These complexes phosphorylate the tumor suppressor protein Retinoblastoma (pRb), releasing the transcription factor
E2F and allowing the expression of genes required in S phase (Nevins, J. R. Science 1992, 258, 424-429; Lavia, P. BioEssays 1999, 21, 221-230). Blocking the activity of the
Cdkd/cyclin D and Cdk2/cyclin E complexes arrests the cell cycle in G; phase. For
Co 30 example, the proteins of the INK4 family, including p16™%* which block the kinase activity of the Cdk4/cyclin D complex, cause arrest in G; (Sherr, C.J]. Science 1996, 274, 1672-1677). The specific block has been reviewed (Vidal, A. Gene 2000, 247, 1-15).
Recent experiments show that the complex of Cdkd4 with cyclin D3 also plays a role in cell cycle progression through G; phase. Inhibition of this complex, either by pl6 or
- using a‘ dominant negative Cdkd, results in arrest in G, phase in cells that do not express
PRb (Gabrielli B. G. et al. J. Biol, Chem. 1999, 274, 13961-13969). . . Numerous defects in the pRb pathway have been shown to be involved in various cancers. For example, overexpression of Cdk4 has been observed in cases of hereditary . 5 melanoma (Webster, K. R. Exp. Opin. Invest. Drugs 1998, 7, 865-887); cyclin D is overexpressed in many human cancers (Sherr, C. J. Science 1996, 274, 1672-1677); p16 is mutated or deleted in many tumors (Webster, K. R. Exp. Opin. Invest. Drugs 1998, 7, 865- 887); and pRb function is lost through mutation or deletion in many human cancers (Weinberg, R. A. Cell 1995, 81, 323-330). Defects in this pathway have also been shown + to have an effect on prognosis. For example, loss of p16 is correlated with poor prognosis in non-small-cell lung carcinoma (NSCLC) and malignant melanoma (Tsihlias, J. et al.
Annu. Rev. Med. 1999, 50, 401-423). Abnormalities of cyclin D1'and/or pRb at the gene and/or expression level were present in more than 90% of a series of non-small cell lung cancer specimens, indicating that cyclin D1 and/or pRb represent an important step in lung tumorigenesis (Marchetti, A. et al. Int. J. Cancer 1998, 75, 573-582). In 49 out of 50 pancreatic carcinomas (98%), the pRb/p16 pathway was abrogated exclusively through inactivation of the p16 gene and cyclin D connected (Schutte, M. et al. Cancer Res. 1998, 57,3126-3134). For a review on the relation between expression of pRb and the cyclin/cyclin dependent kinases in a number of tissues see Teicher, B.A.. Cancer
Chemother. Pharmacol. 2000, 46, 293-304.
Because of the involvement of the Cdk4/cyclin D/pRb pathway in human cancer through its role in regulating progression of the cell cycle from G; to S phase, and the potential therapeutic benefit from modulating this pathway, there has been considerable interest in agents that inhibit or promote elements of this pathway. For example, effects on cancer cells have been shown using antibodies, antisense oligonucleotides and overexpression or addition of proteins involved in the pathway. See, e.g., Lukas, J. et al.
Nature 1995, 79, 573-582; Nevins, J. R. Science 1992, 258, 424-429; Lim, I. K. et al.
Molecular Carcinogenesis 1998, 23, 25-35; Tam, S. W. et al. Oncogene 1994, £, 2663-2674;
Driscoll, B. et al. Am. J. Physiol. 1997, 273 (Lung Cell. Mol. Physiol. ), 1.941-1.949; and
Sang, J. et al. Chin. Sci. Bull. 1999, 44, 541-544).
The role of cdks in the regulation of cellular proliferation is thus well established.
For example, as shown above, there is an extensive body of literature validating the use of compounds inhibiting targets in the Cdk4 , Cdk2 and Cdk1 pathways as anti-proliferative : therapeutic agents. Inhibitors of cellular proliferation thus act as reversible cytostatic ; agents that are useful in the treatment of disease processes which feature abnormal cellular growth, such as cancers and other cell proliferative disorders including, for example inflammation (e.g. benign prostate hyperplasia, familial adenomauosis, oo
: PCT/EP2004/000971 polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, inflammatory bowel disease, transplantation rejections infections), viral infections (including, but not limited to herpervirus, poxvirus, Epstein-Barr virus), autoimmune disease (e.g. lupus, rheumatoid arthritis, psoriasis, inflammatory bowel disease), neurodegenerative disorders (including but not limited to Alzheimer’s disease), and neurodegenerative diseases (e.g. Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy, and cerebral degeneration).
Several distinct classes of small molecules have been identified as inhibitors of
Cdks: olomoucine and other purine analogs, flavopiridol, staurosporine, UCN-01 and other indolocarbazoles, 9-hydroxyellipticine, indirubin, paullones, diaryl ureas, quinazolines, indopyrazoles, [2,3-d] pyridopyrimidines, fascaplysin, aminothiazoles, diaminothiazoles, pteridinones, and pyrazoles or example (Carlson et. al., Cancer Res. 1996, 56, 2973-2978: De Azevedo et al., Eur. J. Biochem., 1997, 243, 518-526; Bridges, A.].,
Exp. Opin. Ther. Patents. 1995, 5, 1245-1257; Reinhold et al., J. Biol. Chem. 1998, 278, 3803-3807; Kakeya, H. et. al., Cancer Res.. 1998, 38, 704-710; Harper, J.W., Cancer
Surveys 1997, 29, 91-107; Harrington, E.A, etal., Proc Natl. Acad. Sci. USA 1998, 95, 11945-11950; Meijer, L., et al., Eur. J. Biochem. 2000, 267, 1-13; Garrett, M.D. et. al,
Current Opin. Genetics Develop. 1999, 9, 104-111; Mgbonyebi, O. P. et al., Cancer Res.. 1999, 59, 1903-1910; Hoessel et al., Nature Cell Biology. 1999, 1, 60-67; Zaherevitz et al.,
Cancer Res., 1999, 59, 2566-2569; Honma, T., et al, 271% National ACS Meeting. 2001:
Medi 136; Sielecki, T.M., et al., Bioorg. Med. Chem. Lett. 2001, 11, 1157-1160; Nugiel, D.
A. etal, J. Med. Chem., 2001, 44, 1334-1336; Fry, D. W. etal, J. Biol. Chem. 2001, 276, 16617-15523; Soni, R., et al., Biochem. Biophys. Res. Commun. 2000, 275, 877; Ryu, C-K. et al., Bioorg. Med. Chem. Lett., 2000, 10, 461; Jeong, H-W.,, etal, Bioorg. Med. Chem.
Lett. 2000, 10, 1819; Toogood et al., J. Med. Chen., 2000, 43, 4606-4616; Chong, W.,
Fischer, Curr. Opin. in Drug Discov. and Develop., 2001, 4, 623-634, WO0009921845,
Toogeod. P., WO0119825, Toogood P., WO0138315, Reich S.H., WO0179198, Webster,
K. US 6,262,096.
The class of diaminopyrimidines is represented by compounds of formula
AN
9
Sw . af stated to inhibit Cdk4 and FAK3. See WO0012485 (Astra Zeneca).
AMENDED SHEET
-10- SE
WO9118887 (Smith Kline Beecham) relates to diaminopyrimidines of formula . AR! - 4 ’
Be
RN ONRR® that are stated to inhibit gastric secretion.
WO0039101 (Astra Zeneca) relates to pyrimidine compounds of formula 1
QR
NT R
A ~
Q—N N
H stated to act as anti-cancer agents. :
WO0164653 (Astra Zeneca) relates to pyrimidine compounds of the formula 2
N~ SN . rR described to act as Cdk inhibitors and FAK inhibitors.
WQO0164654 (Astra Zeneca) relates to pyrimidine compounds of formula por
HM :
Ny . R' described to act as Cdk inhibitors and FAK inhibitors. ’
Additionally, WO0164656 (Astra Zeneca) relates to pyrimidine compounds of formula. : Co Co
. q y Sn : | LA C
R' : also described as Cdk inhibitors and FAK inhibitors.
For reviews of compounds inhibiting the Cdk4/cyclin D pathway see: Harris, W. and Wilkinson, S., Emerging Drugs.. 2000, 5, 287-297; Dumas, J., Exp. Opin. Ther. Patents. 5 . 2001, 11, 405-429; Sielecki T., et. al., J. Med. Chem.. 2000, 43, 1-18.
The present invention relates to novel diaminopyrimidines of the formula
NH, O
NT R2
A i) N 1
R I wherein
R' is selected from the group consisting of heterocycle and lower alkyl-heterocycle, wherein the heterocycle moiety in both instances optionally may be substituted by up to four substituents independently selected from
H, - lower alkyl, : lower alkyl substituted by oxo, OR", COR", NR’RS, S(0)aR or
C(O)NR’RS,
CO,R’,
COR", : COR",
C(O)NRVRY,
S(O)aR", 0X0, ~ ORY or
NR’RS;
-12- | SE - aryl; aryl substituted by -S(0)4-R",
NR’RS, carbonyl, carbonyl substituted by lower alkyl, OR" or NR’RS, lower alkyl, lower alkyl substituted by OR'® or NR°RS, 10. OR? or .
Halogen; cycloalkyl; cycloalkyl substituted by OR’, NR’R® or S(O), R** lower alkyl; and lower alkyl substituted by
NR’R®
NR"SO,R",
COR", :
S(O)R", heterocycle, heterocycle substituted by : lower alkyl,
COR"? or
SOR, h heteroaryl, heteroaryl substituted by lower alkyl, _ CORY, or
SOR", aryl, and aryl substituted by lower alkyl, ~~ halogen,
-13- SE. } © NR°RS,
CORY, or
CORY}
R® is selected from the group consisting of aryl, heteroaryl, cycloalkyl and heterocycle, wherein each may be substituted by up - to four substituents independently selected from the group consisting of lower alkyl, lower alkyl substituted by halogen or OR, v halogen,
OR",
NO,
CN,
NR°RS, $(0)x-R’ and
SE SO,-NR"R";
R’® and R® are each independently selected from the group consisting of
H; lower alkyl; : lower alkyl substituted by oxo, CO,R'2, ORY, NRR", C(O)NR"R™, SO,R',
NSO,R', heteroaryl, heterocycle, or heterocycle substituted by oxo; cycloalkyl; cycloalkyl substituted by CO,R'%, OR'%, NR" R'*, C(O)NR"R" or SO,R'® aryl; aryl substitut=d by NRPRY, ORY, CO,R'2, C(O)NRPR , SO,RY, halogen, lower alkyl, or lower alkyl substituted by halogen, OR'?, oxo, CO,R", C(O)NRPR" or ’ NRIPRY : . : SO.R™;
CORY;
COR'% and
14-0 oo ) OR"? wo | o or alternatively, NR R® can form a ring having 3 to 7 ring atoms, said ring optionally : including one or more additional N or O ring atoms or the group SO, and optionally being substituted by OH, oxo, NR"’R*, lower alkyl and lower alkyl substituted by OR'%;
R’ is selected from the group consisting of " H; : lower alkyl; lower alkyl substituted by OR'?, COR", NR°R, or C(O)NR’R® halogen; 0X0; aryl; aryl substituted by up to three substituents independently selected from lower alkyl, halogen and NR°R® cycloalkyl; cycloalkyl substituted by OH, oxo, or NH.
SO;R'* and | 3
COR";
R® is selected from the group consisting of
H; oo 20 lower alkyl; lower alkyl substituted by NR’R® heterocycle; and ~ heterocycle substituted by lower alkyl, CO.R'? or SO:R' > so ) R’ isselected from the group consisting of
H; and lower alkyl;
R'is selected from the group consisting of lower alkyl; aryl; and aryl substituted by halogen or NR’R%
R'" is selected from the group consisting of :
H; lower alkyl; and lower alkyl substituted by oxo or halogen; * R'? is selected from the group consisting of
H; lower alkyl; and lower alkyl substituted by NR°R® or OR";
R" and R" are each independently selected from the group consisting of
Hj lower alkyl; lower alkyl substituted by CO.R'%, OR'?, NR’R®, C(O)NR’R®, SO,R"’, NSO,R"?, heteroaryl, heterocycle, or heterocycle substituted by oxo; cycloalkyl; cycloalkyl substituted by CO,R'?, OR'?>, NRR®, C(O)NR’R’ or SO.R'; aryl; aryl substituted by NR’R®, OR'?, CO,R"2, CONR’R’, SO,R", halogen, lower alkyl, and lower alkyl substituted by halogen, OR? 0x0, CO,RY, C(O)NR’R® or NR°R®
SOR;
COR
. CORY; and : OR12 wo lo
: : PCT/EP2004/000971 or alternatively, -NR'’R' can form a ring having 3 to 7 ring atoms, said ring optionally including one or more additional N or O ring atoms and optionally being substituted by
OH, oxo, NRR®, lower alkyl and lower alkyl substituted by ORY;
R!® is selected from the group consisting of aryl; aryl substituted by the group halogen, COR", SOR, COR", lower alkyl and lower alkyl substituted by halogen, ORY, oxo, COR'2, C(O)NR°R® or NRR’; heteroaryl; heteroaryl substituted by the group halogen, CO,RY, SO,R', CORY, lower alkyl and lower alkyl substituted by halogen, OR'?, oxo, CO,R'2, C(O)NR®R® or NR°R’;
NR°RS; lower alkyl;
Jower alkyl substituted by halogen, OR", oxo, CORY, C(O)NR’R® or NR’R’; heterocycle, and heterocycle substituted by the group CO,R", CORY, SO.RY, COR? lower alkyl,
C(O)NR’R®or NR’R%;
R!S and RY are each independently selected from the group consisting of
H; and lower alkyl; or, alternatively, the group _NR¥RY can form a ring having 3 to 7 ring atoms, said ring optionally including one or more additional N or O ring atoms and optionally being substituted by lower alkyl, OH, oxo and NHz: and n is0,1 012; or the pharmaceutically acceptable salts or esters thereof.
These compounds inhibit cyclin-dependent kinases, most particularly Cdk4. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.
AMENDED SHEET
-17- oo
The present invention also relates to pharmaceutical compositions comprising one or more compounds of the invention, or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier or excipient.
The present invention further relates to a method for treating or controlling cancer, more particularly the treatment or control of a solid tumor, most particularly to the treatment or control of breast, lung and colon and prostate tumors by administering to a patient in need of such therapy a therapeutically effective amount of a compound of formula I, or a pharmaceutically salt or ester thereof. . Finally, this invention also relates to a process for the preparation of compounds of formula I and to novel intermediate compounds useful in the preparation of a compound of formula I. RT
As used herein, the following terms shall have the following definitions. : "Aryl" means a monovalent, monocyclic or bicyclic, aromatic carbocyclic hydrocarbon radical, preferably a 6-10 membered aromatic aromatic ring system.
Preferred aryl groups include, but are not limited to, phenyl, naphthyl, tolyl and xylyl. "Carbonyl" means the radical C=0. ~ "Cycloalkyl" means a non-aromatic, partially or completely saturated monovalent cyclic hydrocarbon radical containing 3 to 8 atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. "Effective amount" means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. “Halogen” means fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine. “Hetero atom” means an atom selected from N, O and S. "Heteroaryl" means an aromatic heterocyclic ring system containing up to two rings. Preferred heteroaryl groups include, but are not limited to, thienyl, furyl, indolyl, ) pyrrolyl, pyridinyl, pyridine, pyrazinyl, oxazolyl, thiaxolyl, quinolinyl, pyrimidinyl, imidazolyl, benzofuranyl and tetrazolyl. EE "Heterocycle" or "heterocyclyl" means a saturated or partially unsaturated, non- aromatic cyclic radical of 3 to 8 ring atoms in which from 1to 3 ring atoms are hetero "atoms selected from nitrogen, oxygen, S(O), (where n is an integer from 0 to 2), ora
-18- oo ) combination thereof, the remaining ring atoms being C. Examples of preferred heterocycles are piperidine, piperazine, pyrrolidine, morpholine, indoline, tetrahydropyranyl, thiomorpholino, pentamethylene sulfide, and pentamethylene sulfone. “ICs” refers to the concentration of a particular compound according to the invention required to inhibit 50% of a specific measured activity. ICsp can be measured, inter alia, as is described in Example390A4, infra. “K,” refers to a measure of the thermodynamic binding of the ligand/inhibitor (that
Lisa compound according to the invention) to the target protein. K; can be measured, inter alia, as is described in Example 390B, infra. “Lower alkyl” alone or in conjunction with another term, e.g. lower alkyl- heterocycle, denotes a straight-chain or branched saturated aliphatic hydrocarbon having 1 to 6, preferably 1 to 4, carbon atoms. Typical lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, 2-butyl, pentyl, hexyl and the like. "Oxo" means =O. “Pharmaceutically acceptable ester” refers to a conventionally esterified compound of formula I having a carboxyl group, which esters retain the biological effectiveness and properties of the compounds of formula I and are cleaved in vivo (in the organism) to the corresponding active carboxylic acid. Examples of ester groups which are cleaved (in this case hydrolyzed) in vivo to the corresponding carboxylic acids (R¥C(=0)OH) are lower alkyl esters which may be substituted with NR*'R*? where R* and R*? are lower alkyl, or where NR*'R*? taken together form a monocyclic aliphatic heterocycle, such as pyrrolidine, piperidine, morpholine, N-methylpiperazine, etc.; acyloxyalkyl esters of the formula R¥C(=0)OCHR*0C(=0)R* where R® is hydrogen or methyl, and R* is lower alkyl or cycloalkyl; carbonate esters of the formula R¥*C(=0)OCHR* OC(=0)OR* where R® is hydrogen or methyl, and R® is lower alkyl or cycloalkyl; or ' aminocarbonylmethyl esters of the formula R®C(=0)OCH,C(=0)NR*'R* vihere RY and R* are hydrogen or lower alkyl, or where NR*R* taken together form a monocyclic aliphatic heterocycle, such as pyrrolidine, piperidine, morpholine, N-methylpiperazine, etc. a
Examples of lower alkyl esters are the methyl, ethyl, and n-propyl esters, and the : like. Examples of lower alkyl esters substituted with NR*R* are the diethylaminoethyl, 2- (4-morpholinyl)ethyl, 2-(4-methylpiperazin-1-yl)ethyl esters, and the like. Examples of acyloxyalkyl esters are the pivaloxymethyl, 1-acetoxyethyl, and acetoxymethyl esters. N
Examples of carbonate esters are the 1-(ethoxycarbonyloxy)ethyl and 1-
(cyclohexyloxycarbonyloxy) ethyl esters. Examples of aminocarbonylmethyl esters are the
N,N-dimethylcarbamoylmethyl and carbamoylmethyl esters.
Further information concerning examples of and the use of esters for the delivery of pharmaceutical compounds is available in Design of Prodrugs. Bundgaard Hed. ’ 5 (Elsevier, 1985). See also, H. Ansel et. al., Pharmaceutical Dosage Forms and Drug
Delivery Systems (6th Ed. 1995) at pp. 108-109; Krogsgaard-Larsen, et. al., Textbook of
Drug Design and Development (2d Ed. 1996) at pp. 152-191. “Pharmaceutically acceptable salt” refers to conventional acid-addition salts or , base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluene sulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide. The chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See, e.g,
H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196 and 1456-1457. “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered: “Substituted,” as in substituted alkyl, means that the substitution can occur at one or more positions and, unless otherwise indicated, that the substituents at each substitution site are independently selected from the specified options. “Therapeutically effective amount” means an amount of at least one compound of
Formula I, or a pharmaceutically acceptable salt or ester thereof, that significantly : inhibits proliferation and/or prevents differentiation of a human tumor cell, including human tumor cell lines.
: In one embodiment, the present invention relates to compounds of formula I : NH, O . NT R2
PY = i) N : : : R 1, or the pharmaceutically acceptable salts or esters thereof, wherein R' and R® are as , defined above.
In a preferred embodiment of the compounds of formula I, R? is phenyl, preferably phenyl substituted by halogen, most preferably F, or OR"? wherein R'? is lower alkyl. Ina most preferred embodiment, R? is phenyl substituted by one or two F molecules and one
OR"? group wherein R'is lower alkyl, preferably methyl.
In another preferred embodiment of the compounds of formula I, R? is as defined above and R' is selected from the group (3 A ) SE No
R3 - OX Rs (a), (b), (c)
Ré
R4 4 .
REC i \ ZN
Re R® RS OR". (d), (e)s (0,
-21- SE. : oe
R# RY i $(0),
NJ | Lis
RS Re Re (2) (h) and - (i), wherein ‘Rs selected from the group consisting of
H, or lower alkyl, lower alkyl substituted by oxo, OR", CO,R'?, NR’R?, SO,R** or C(O)NRRS,
COR,
CORY,
C(O)NR’R’, and
SOR";
R* is selected from the group consisting of
H, y
OR! : Co lower alkyl,
NRR’,
NO, 0X0
CN, and - halogen;
RY is selected from the group consisting of
H,
OR! 1 lower alkyl,
NR°R’,
NO.,
CN, and halogen;
R’and R® are each independently selected from the group consisting of
: PCT/EP2004/000971
H, lower alkyl, lower alkyl substituted by oxo, CO;R'2, OR, NRPR™, C(O)NR"R™, SO.RY,
NSO;R'3, heteroaryl, heterocycle, or heterocycle substituted by oxo, cycloalkyl, cycloalkyl substituted by CO;R'2, OR™2, NR"R", C(O)NRR' or SOR”, aryl, aryl substituted by NR°R*, OR", CO,R", C(O)NR"R', SOR", halogen, lower alkyl, and lower alkyl substituted by halogen, OR'?, oxo, CORY, C(O)NRPR" and
NRPR'™;
SOR",
CO:RY,
COR", and
OR™2
R11 OL | = or alternatively, -NR°R® can form a ring having 3 to 7 atoms, said ring optionally including one or more additional N or O atoms and optionally being substituted by OH, oxo, NRPR", lower alkyl and lower alkyl substituted by OR'%
R is selected from the group consisting of
H, lower alkyl, lower alkyl substituted by OR", CO;R'?, NR’R’, or CONR’R, halogen, oxo, aryl, aryl substituted by up to three substituents independently selected from lower alkyl, halogen, and NR°R’, cycloalkyl, cycloalkyl substituted by OH, oxo, or NHo,
SOR", and
COR";
R® is selected from the group consisting of
H, lower alkyl,
Jower alkyl substituted by NR’R®,
AMENDED SHEET
-23- a - heterocycle, and heterocycle substituted by lower alkyl, CO;R™? or SOR;
R'® is selected from the group consisting of lower alkyl, aryl, and aryl substituted by halogen or NR°R;
R'" is selected from the group consisting of
H, lower alkyl, and lower alkyl substituted by oxo and halogen;
R'is selected from the group consisting of
H, lower alkyl, and lower alkyl substituted by halogen, oxo, NR°R® or OR"};
R” and R" are independently selected from the group consisting of
H, a lower alkyl, lower alkyl substituted by CO,R'2, ORY, NR°RS, C(O)NR'RS, SO.R'®, NSO,R'2, heteroaryl, heterocycle, or heterocycle substituted by oxo, cycloalkyl, cycloalkyl substituted by CO,R'?, OR", NR’R®, C(O)NRR® or SO,R", aryl, aryl substituted by NR°R®, OR'%, CO;R'?, C(O)NR’R?, SO,R*, halogen, lower alkyl, and lower alkyl substituted by halogen, OR", 0x0, CO,R'%, C(O)NR’R® and NR°RS;
SOR",
CO.R",
CORY, and
OR12 i
RO ~ AO : or alternatively, -NR'’R" can form a ring having 3 to 7 ring atoms, said ring optionally including one or mors additional N or O ring atoms and optionally being substituted by
OH, oxo, NR’R®, lower alkyl and lower alkyl substituted by OR'%;
R"” is selected from the group consisting of aryl, Ce aryl substituted by the group halogen, COR"? SOR’, COR", lower alkyl and lower alkyl substituted by halogen, OR'?, 0x0, CO,R'%, C(O)NR’R® or NR°RS, : heteroaryl, : . Lo SE heteroaryl substituted by the group halogen, COR", SO.R'%; COR? lower alkyl and lower alkyl substituted by halogen; ORY, 0XO0, CORY, C(O)NR°R® or NR? RS,
- | 224 - Co . NR°R’, lower alkyl, lower alkyl substituted by the group halogen, OR'?, oxo, CO,R'2, C(O)NR°R® or : NR’RS, heterocycle, and : heterocycle substituted by the group CO,R*?, COR? SO;R", lower alkyl
C(O)NR’R® or NR°RS;
X isselected from the group consisting of
S, SO, SO,, and O; and n is0,1lor2; or the pharmaceutically acceptable salts or esters thereof, Co
In another preferred embodiment, the invention relates to compounds of formula : NH, O
R21
N 7
R18 20 bg :
HN R10 @), 18 : wherein R® and R* are as defined above and R'®, R”, R®* and R* are each independently selected from lower alkyl, halogen and OR. Preferably, R? is selected from the group
CO,R’, COR? and SO,RY.
Most preferably R? is SO,R'* and RY is lower alkyl or NR°R®, Preferred R’ groups include H, OR" and lower alkyl. Preferred R’ and R® groups are those wherein the group -NR’R® forms a ring having 3 to 7 ring atoms, said ring optionally including one or more additional N or O ring atoms and optionally being substituted by OH, oxo and NH, lower alkyl or lower alkyl substituted by OR'2.
Examples of compounds of formula I(a) include: oe Co - . 4-[4-amino-5-( 2-methoxy-benzoyl)-pyrimidin-2-ylamino -piperidine- 1 carboxylic acid - ethyl ester (Example 9), Co oo :
w WO 2004/069139 PCT/EP2004/000971 -25- S. 4-[4-amino-5-(2,6-difluoro-benzoyl)-pyrimidin-2-ylamino)-piperidine- 1-carboxylic acid ethyl ester (Example 16), 4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine- 1- carboxylic acid ethyl ester (Example 51), 1-[4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]- piperidin-1-yl] -ethanone
Co (Example 20), 1-[4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino)-piperidin-1-yl]-propan-1- one (Example 21), 1-[4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl]-butan-1- one (Example 22), oT 1-[4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl}-3-methyl- butan-1-one ( Example 23), : 1-[4-[4-Amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl] -3- diethylamino-propan-1-one (Example 24), 4-[4-amino-5-(2-methyl-benzoyl)-pyrimidin-2-ylamino]-piperidine-1-carboxylic acid ethyl ester (Example 35), 4- (4-Amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidine-1-carboxylic acid methyl ester (Example 17), 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1-carboxylic acid propyl ester (Example 18), 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1-carboxylic acid iso-butyl ester ( Example 19), 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1-carbozylic acid methylamide (Example 25), 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1-carboxylic acid ethylamide (Example 26), ) 4- [4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino} -piperidine-1 -carboxylic acid propylamide (Example 27), -_ PERI Co
-26- C : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2-methoxy- phenyl)-methanone (Example 28), : . [4-amino-2-(1-ethanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]- (2-methoxy- phenyl)-methanone (Example 29),
[4-amino-2-[1-(propane-1-sulfonyl)-piperidin-4-ylamino)-pyrimidin-5-yl]-(2- methoxy-phenyl)-methanone (Example 30), 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl) -pyrimidin-2-ylamino]-piperidin-1-yl]- ethanone (Example 62), 4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- :
carboxylic acid methyl ester (Example 60) 4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- carboxylic acid propyl ester (Example 61), : 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl]- propan-1l-one (Example 63),
1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl]- butan-1-one (Example 64), a 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidine-1-carboxylic acid dimethylamide (Example 57), [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(5-fluoro-2-
methoxy-phenyl)-methanone ( Example 65), [4-amino-2-(1-ethanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(5-fluoro-2- methozy-phenyl)-methanone (Example 66),
* [4-amino-2-[ 1-(propane-1-sulfonyl)-piperidin-4-ylamino]-pyrimidin-5-y1]-(5-flucro-2- methoxy-phenyl)-methanone (Ezample 67), [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2-fluoro- phenyl)-methanone (Example 41), [4-amino-2-( I-ethanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2-fluoro-phenyl)- methanone (Example 42), 7 CL : Co Le ;
27. S ) 4-[4-amino-5-(2-fluoro-benzoyl)-pyrimidin-2-ylamino}-piperidine-1-carboxylic acid ethyl ester (Example 40), [4-amino-2-(1 -trifluoromethanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(5- fluoro-2-methoxy-phenyl)-methanone (Example 68), 4-[4-amino-5-( 5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidine-1- sulfonic acid dimethylamide (Example 160), 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl]- 2-dimethylamino-ethanone (Example 81), 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl}- 2-diethylamino-ethanone (Example 82), oT 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl]- 2-morpholin-4-yl-ethanone (Example 83), : 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl]- 3-dimethylamino-propan-1-one (Example 84), 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl}- 3-diethylamino-propan-1-one (Example 85), 1-[4-[4-amino-5-( 5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin-1-yl]- 3-piperidin-1-yl-propan-1-one (Example 86), 1-[4~[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl}- 3-morpholin-4-yl-propan-1-one (Example 87), [4-amino-2-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-ylamino}-pyrimidin-5- y1]-(5-fluoro-2-methoxy-phenyl)-methanone (Example 161), [4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-v1]- acetic acid methyl ester (Example 159), 1-{4- [4-amino-5-(2,6-difluoro-3-methoxy-benzoyl)-pyrimidin-2-ylamino) -piperidin-1- yl]-ethanone (Example 90), ) [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-y1] -(2,6-difluoro-3- methoxy-phenyl)-methanone (Example 91), EE . RE oT
S28. oo ; 4-[4-amino-5-(2,6-difluoro-3-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidine-1- carboxylic-acid methyl ester (Example 94), : 1-[4-[4-amino-5-(2-ethoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl} -ethanone (Example 97), ‘
[4-amino-2-[1-(thiophene-3-sulfonyl)-piperidin-4-ylamino] -pyrimidin-5-yl] -(5-fluoro- 2-methoxy-phenyl)-methanone (Example 153), [4-amino-2-[1-(benzo[b]thiophene-3-sulfonyl)-piperidin-4-ylamino}-pyrimidin-5-yl]- (5-fluoro-2-methoxy-phenyl)-methanone ( Example 154), [4-amino-2-{1-(1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-ylamino}-
pyrimidin-5-yl}-(5-fluoro-2-methoxy-phenyl)-methanone (Example 155), 3-{4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- sulfonyl]-thiophene-2-carboxylic acid methyl ester (Example 156), (4-amino-2-[1-(2,5-dimethyl-thiophene- 3-sulfonyl)-piperidin-4-ylamino]-pyrimidin-5- y1]-(5-fluoro-2-methoxy-phenyl)-methanone (Example 152),
4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino}-piperidine-1- carboxylic acid cyclohexylamide (Example 145), ” 1-[4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin-1- yl]-ethanone (Example 104), (4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2,3-difluoro-6-
methoxy-phenyl)-methanone (Example 105), [4-amino-2-(piperidin-4-ylamino)-pyrimidin-5-yl]-(2-methoxy-phenyl)-methanone (Example 11),
[4-amino-2-{piperidin-4-ylamino)-pyrimidin-5-y1] -(5-fluoro-2-methoxy-phenyl)- methanone (Example 59), oo 25 [4-amino-2-(piperidin-4-ylamino)-pyrimidin-5-yl]-(2,3-difluoro-6-methoxy-phenyl)- methanone (Example 107), i 1-[4-[4-amino-5-(2,3 ,4-trifluoro-6-methoxy-benzoyl) -pyrimidin-2-ylamino] -piperidin- 1-yl]-ethanone (Example 204), Sl nL Bh Co N Lo CL
-29- J - [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(3,4,5-trifluoro- 2-methoxy-phenyl)-methanone (Example 206), : [4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -( 2,3 4-trifluoro- 6-methoxy-phenyl)-methanone (Example 207), [4-amino-2-[1- (2-methanesulfonyl-ethyl) -piperidin-4-ylamino] -pyrimidin-5-y1] -(5- fluoro-2-methoxy-phenyl)-methanone (Example 209), 1-[4-[4-amino-5-(5-fluoro-2-methyl-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-y1]- ethanone (Example 211), : (4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(5-fluoro-2- : methyl-phenyl)-methanone (Example 213), oT [4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(5-fluoro-2- trifluoromethyl-phenyl)-methanone (Example 214), [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino) -pyrimidin-5-yl]-(5-fluoro-2- 1sopropoxy-phenyl)-methanone (Example 215), [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2-ethoxy-5- fluoro-phenyl)-methanone (Example 216), [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2-ethyl-5- fluoro-phenyl)-methanone (Example 217), [4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2-methoxy-4- trifluoromethyl-phenyl)-methanone ( Example 218), 4-[4-amino-5-(2-fluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- carboxylic acid tert-butyl ester (Example 222), [4-amino-2-(piperidin-4-ylamino)-pyrimidin-5-yl]-(2-fluoro-6-methozy-phenyl)- methanone (Example 223), [4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-71] -(2-fluoro-6- methoxy-phenyl)-methanone (Example 224), 1-[4-[4-amino-5- (2-fluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin- 1-yl]- 2,2,2-trifluoro-ethanone (Example 225), — PEER REE
-30- SE ) [4-amino-2-[1-(3-chloro-propane-1-sulfonyl)-piperidin-4-ylamino] -pyrimidin-5-yl]- (2,3-difluoro-6-methoxy-phenyl)-methanone (Example 226), (4-amino-2-[1-[3-(2-hydroxy-1-methyl-ethylamino)-propane-1-sulfonyl] _piperidin-4- ylamino]-pyrimidin®5-yl)-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 227), (4-amino-2-[1-[3-(4-methyl-piperazin-1-yl)-propane-1-sulfonyl] piperidin-4-ylamino) -
: pyrimidin-5-y1)-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 228), (4-amino-2-[1-[3-((R)-1-hydroxymethyl-propylamino)-propane-1-sulfonyl]-piperidin- 4-ylamino|-pyrimidin-5-yl)-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example
229), [4-amino-2-[1-(3-hydroxy-propane-1-sulfonyl)-piperidin-4-ylamino]-pyrimidin-5-yl]- (2,3-difluoro-6-methoxy-phenyl)-methanone (Example 230), [4-amino-2-[1-(3-pyrrolidin-1-yl-propane-1-sulfonyl)-piperidin-4-ylamino}-pyrimidin-
: 5-y1]-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 231), [4-amino-2-[1-(3-morpholin-4-yl-propane-1-sulfonyl)-piperidin-4-ylamino]-
pyrimidin-5-yl]-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 232), [4-amino-2-(1-[3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propane-1-sulfonyl}-piperidin- 4-ylamino)-pyrimidin-5-yl] -(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 233), : [4-amino-2-(1-[3-[(2-methoxy-ethyl)-methyl-amino]-propane-1-sulfonyl]-piperidin-4-
ylamino)-pyrimidin-5-yl]-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 234), (4-amino-2-[1-[3-(2-hydroxy-1,1-dimethyl-ethylamino)-propane- 1-sulfonyl] -piperidin- 4-ylamino]-pyrimidin-5-y1)-(2,3-difluoro-6-methozxy-phenyl)-methanone (Example 235),
(4-amino-2-[1-[3-(2-hydroxy-propylamino)-propane- 1-sulfonyl]-piperidin-4-ylamino]-
pyrimidin-5-y1)-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 236), (4-amino-2-[1-[3-((S)-2-hydroxy- 1-methyl-ethylamino)-propane-1-sulfonyl]-piperidin-
. 4-ylamino]-pyrimidin-5-y1)-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 237), Co I (4-amino-2-[1- (3-((R)-1-hydroxymethyl-2-methyl-propylamino)-propane- I-sulfonyl]-
piperidin-4-ylamino]-pyrimidin-5-y})-( 2,3-difluoro-6-methoxy-phenyl)-methanone (Example 238), oo | SE
-31- SE (4-amino-2-[1-[3~((R)-2-hydroxy-1-methyl-ethylamino)-propane-1-sulfonyl] - piperidin-4-ylamino]-pyrimidin-5-yl)-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 239), (4-amino-2-[1-[3-({S)-1-hydroxymethyl-propylamino)-propane-1-sulfonyl}-piperidin-
' 5 4-ylamino)-pyrimidin-5-y1)-(2,3-difluoro-6-methoxy-phenyl)-methanone (Example 240), [4-amino-2-(1-[3-[3-hydroxy-1-(2-hydroxy-ethyl)-propylamino] -propane-1-sulfonyl]- piperidin-4-ylamino)-pyrimidin-5-yl]-(2,3-difluoro-6-methoxy-phenyl)-methanone
(Example 241),
[4-amino-2-[1-(3-chloro-propane-1-sulfonyl)-piperidin-4-ylamino]-pyrimidin-5-yl]-(5- fluoro-2-methoxy-phenyl)-methanone (Example 242), Co [4-amino-2-(1-[3-[(2-methoxy-ethyl)-methyl-amino]-propane-1-sulfonyl}-piperidin-4- ylamino)-pyrimidin-5-yl]-(5-fluoro-2-methoxy-phenyl)-methanone (Example 243), [4-amino-2-(1-[3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propane-1-sulfonyl] -piperidin-
4-ylamino)-pyrimidin-5-yl]-(5-fluoro-2-methoxy-phenyl)-methanone (Example 244), (4-amino-2-{1-[3-((S)-2-hydroxy-1-methyl-ethylamino)-propane- 1-sulfonyl} -piperidin- 4-ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 245), (4-amino-2-[1-[3-((R)-1-hydroxymethyl-propylamino)-propane-1-sulfonyl] -piperidin- 4-ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 246),
(4-amino-2-[1-[3-(2-hydroxy-propylamino)-propane-1-sulfonyl]-piperidin-4-ylamino]- pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 247), (4-amino-2-[1-[3-((R)-1-hydroxymethyl-2-methyl-propylamino)-propane-1-sulfonyl]- piperidin-4-ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 248),
(4-amino-2-[1-[3-(2-methoxy-1-methyl-ethylamino)-propane-1-sulfonyl]-piperidin-4- ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 249), (4-amino-2-[1-[3-(2-hydroxy-1,1-dimethyl-ethylamino)-propane-1-sulfonyl]-piperidin-
4-ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 250), (4-amino-2-[1-[3-((R)-2-hydroxy-1-methyl-ethylamino)-propane- 1-sulforyl}- _ piperidin-4-ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 251), Co
) -32- oo . (4-amino-2-[1-[3-((S)- 1-hydroxymethyl-propylamino)-propane- I-sulfonyl]-piperidin- 4-ylamino} -pyrimidin-5-yl)-( 5-fluoro-2-methoxy-phenyl)-methanone (Example 252), [4-amino-2-[1-( 4-hydroxy-butane-1 -sulfonyl) -piperidin-4-ylamino) -pyrimidin-5-yl] - (5-fluoro-2-methoxy-phenyl)-methanone (Example 253), ’ 5 [4-amino-2-(1-(4-chloro-butane-] -sulfonyl) -piperidin-4-ylamino] -pyrimidin-5-yl]-(5-
fluoro-2-methoxy-phenyl)-methanone (Example 255),
(4-amino-2-[1-[4-( 4-methyl-piperazin-1-yl)-butane-1 -sulfonyl)-piperidin-4-ylamino]- pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 256),
[4-amino-2-[1-(4-pyrrolidin-1 -yl-butane-1 -sulfonyl)-piperidin-4-ylamino]- pyrimidin-
5-yl]-(5-fluoro-2-methoxy-phenyl)-methanone (Example 257), ~~
(4-amino-2-[1-[4-( 2-hydroxy-propylamino)-butane-1 -sulfonyl]-piperidin-4-ylamino]- pyrimidin-5-y)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 258), [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-y1)-(2,3-difluoro- 5,6-dimethoxy-phenyl)-methanone (Example 261),
[4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2,3-difluoro-6- hydroxy-5-methoxy-phenyl)-methanone (Example 262), [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2,3-difluoro- 5,6-dihydroxy-phenyl)-methanone (Example 263),
[4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2,3-difluoro-5-
hydroxy-6-methoxy-phenyl)-methanone (Example 271), (4-amino-2-[1-(3-chloro-propane- 1-sulfonyl)-piperidin-4-ylamino] -pyrimidin-5-yl]-(5- fluoro-2-methoxy-phenyl)-methanone (Example 272), [4-amino-2-[1-(3-pyrrolidin-1 -yl-propane-1 -sulfonyl)-piperidin-4-ylamino] -pyrimidin- 5-y1}-(5-fluoro-2-methoxy-phenyl)-methanone (Example 273), = 25 acetic acid 3-[4-4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino.- piperidine-1-sulfonyl]-propyl ester (Example 274), ; (4-amino-2-| 1-(3-hydroxy-propane-1 -sulfonyl)-piperidin-4-ylamino]-pyrimidin-5-y1}- (5-fluoro-2-methoxy-phenyl)-methanone (Example 275), ~ B T Lo CL
33. | SE : [4-amino-2-[1-(3-morpholin-4-yl-propane-1 -sulfonyl)-piperidin-4-ylamino]-
Pyrimidin-5-yl]-(5-fluoro-2-methoxy-phenyl)-methanone (Example 276),
N-(3-[4-[4-amino-5-( 5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidine- 1-sulfonyl]-propyl)-methanesulfonamide (Example 277), (4-amino-2-[1-[3-(4-methyl-piperazin-1-yl)-propane-1-sulfonyl] -piperidin-4-ylamino]- : pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone (Example 278), [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(2,3-difluoro-6- _hydroxy-phenyl)-methanone (Example 279), [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-phenyl- : methanone (Example 283), oT 4-[4-amino-5-( 2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino}-piperidine-1- carbaldehyde (Example 284), : 4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- sulfonic acid amide (Example 285), 4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- sulfonic acid acetyl-amide (Example 286), ” rac-(4-amino-2-(3-hydroxy- 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl} - (2,3-difluoro-6-methoxy-phenyl)-methanone (Example 306), rac-[4-amino-2-(3-hydroxy-1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl} - (2,3-difluoro-6-methoxy-phenyl)-methanone (Example 310), rac-(4-amino-2-(1-methanesulfonyl-3-methoxy-piperidin-4-ylamino)-pyrimidin-5-yl]- (2,3-difluore-6-metho:zy-phenyl)-methanone (Ezample 313), rac-4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]-1- methanesulfonyl-piperidin-3-one (Example 314), oo 25 1-[4-[4-amino-5-(2-methoxy-5-methyl-benzoyl)-pyrimidin-2 -ylamino] -piperidin-1-yl]- ethanone (Example 326), [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2-methoxy:5- methyl-phenyl)-methanone (Example 327), . CL I i ’
-34- oo : (4-amino-2-ethylsulfanyl-pyrimidin-5-y1)-(2,5-dimethoxy-phenyl)-methanone (Example 328),
: 1-[4-[4-amino-5-(2,5-dimethoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin-1 1] - ethanone (Example 330), [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2,5-dimethoxy- phenyl)-methanone (Example 331), 1-[4-[4-amino-5-(2,6-dimethoxy-benzoyl)-pyrimidin-2-ylamino}-piperidin-1 -yl}- ethanone (Example 334),
[4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2,6-dimethoxy-
phenyl)-methanone (Example 335), oT 1-[4-{4-amino-5-(5-fluoro-2-methoxy-4-methyl-benzoyl)-pyrimidin-2-ylamino]- piperidin-1-yl]-ethanone (Example 342), : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(5-fluoro-2- methoxy-4-methyl-phenyl)-methanone (Example 343),
[4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(3-fluoro-2,6- dimethoxy-phenyl)-methanone (Example 348), h [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2-ethoxy-3- fluoro-6-methoxy-phenyl)-methanone (Example 349), 1-[4-[4-amino-5-(3-fluoro-6-methoxy-2-methyl-benzoyl)-pyrimidin-2-ylamino]-
piperidin-1-yl]-ethanone (Example 351), [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(3-fluoro-6- methoxy-2-methyl-phenyl)-methanone (Example 352), 1-[4-(4-amino-5-(4-methyl-benzoyl)-pyrimidin-2-ylamino]-pipzridin-1-y1}-ethanone (Example 355),
[4-amino-2-( 1-methanesulfonyl- piperidin-4-ylamino)-pyrimidin-5-yl] -p-tolyl- methanone (Example 356), 1-(4-[4-amino-5-(4-methoxyl-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl] -etharione (Example 359), Co a.
CL ; To os Co
-35- oo [4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(4-methoxy- phenyl)-methanone (Example 360), 1-[4-[4-amino-5-(4-chloro-benzoyl)-pyrimidin-2-ylamino} -piperidin-1-yl] -ethanone (Example 363), ‘ [4-amino-2-(1 methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(4-chloro- phenyl)-methanone (Example 364), 1-{4- [4-amino-5-(4-fluoro-benzoyl)-pyrimidin-2-ylamino) -piperidin-1-yl}-ethanone (Example 367), [4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(4-fluoro-
phenyl)-methanone (Example 368), oT [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(5-fluoro-2,4- dimethoxy-phenyl)-methanone (Example 369), : (4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(4-ethoxy-5- fluoro-2-methoxy-phenyl)-methanone (Example 370),
[4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(3-fluoro-4- methoxy-phenyl)-methanone (Example 373), 4-[4-amino-5-( 5-fluoro-2-methoxy-4-methyl-benzoyl)-pyrimidin-2-ylamino] - piperidine-1-carboxylic acid tert-butyl ester (Example 374), [4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(4-chloro-5- fluoro-2-methoxy-phenyl)-methanone (Example 378), y [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(3,5-difluoro-2- methoxy-phenyl)-methanone (Example 381), [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl)-(2-fluore-5- methoxy-4-methyl-phenyl)-methanone (Example 335), and
[4-amino-2-( -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-( 5-fluoro-2- } methoxy-3-methyl-phenyl)-methanone (Example 388).
Claims (1)
- - 264 - Co : CLATMS1. A compound of the formula NH, O N™ XY R2 Mo i) N 1 R I ** wherein 5s R' is selected from the group consisting of SE heterocycle and lower alkyl-heterocycle, wherein the heterocycle moiety in both instances optionally may be substituted by up to four substituents independently © selected from : H, lower alkyl, lower alkyl substituted by oxo, OR", COR", NR’R®, S(O),R"’ or C(O)NR’R’, . COR’, COR", CORY, : C(O)NRVR™, : S(O)R", 0X0, OR'?, or : NR’R% : : aryl; aryl substituted by ~~ - H, -5(0)a-R", a . NR°R’, carbonyl, : oo _ RE ) carbonyl substituted by lower alkyl, OR? or NR’R®, AVE lower alkyl, = . Co Co oo oo _ : lower alkyl substituted by ORY or NR°RS, } : Ls-265- SE OR’, or Halogen; : : cycloalkyl; . cycloalkyl substituted by OR’, NR°R® or S(O).R"> : lower alkyl; and lower alkyl substituted by NR°R’, y NR'"SO,R",CO.RY, : S(O)R", | oo heterocycle, heterocycle substituted by lower alkyl, COR" or SOR", heteroaryl, heteroaryl substituted by : lower alkyl, CO;RY, or : SOR, } aryl, and : aryl substituted by BN lower alkyl, halogen, NRRS, CORY, or : CORY; R* is selected from the group consisting of ; aryl, heteroaryl, cycloalkyl and heterocycle, wherein each may be substituted by up to four substituents independently selected from the group consisting of, ~~ ~~ loweralkyl, SE ; lower alkyl substituted by halogen or ORY, = SE-266- SE halogen, OR! NO,, CN, NR°R%, $(0),-R’, and SO,-NR*RY; . R’ and R® are each independently selected from the group consisting of . H; lower alkyl; lower alkyl substituted by oxo, CO;R", OR'?, NRR", C(O)NR"R", SOR", NSO,R'?, heteroaryl, heterocycle, or heterocycle substituted by oxo; "cycloalkyl; cycloalkyl substituted by CO,R'2, OR'2, NR" R*, C(O)NR"R™ or SOR" aryl; aryl substituted by NR'*R™, OR'2, CO,R'2, C(O)NR¥R™, SO,R"*, halogen, lower alkyl, or lower alkyl substituted by halogen, OR", oxo, CO,R'%, C(O)NR"R" or NRIR . SOR; CORY; .. COR'* and OR™ Rio 0) ~ o AO . or alternatively, -NR°R® can form a ring having 3 to 7 ring atoms, said ring optionally including one or more additional N or O ring atoms or the group SO, and optionally being substituted by OH, oxo, NR" R!4, lower alkyl and lower alkyl substituted by OR; R” is selected from the group consisting of | Co . - ’ . : Co-267- Co Hj; lower alkyl; : lower alkyl substituted by OR', COR", NRR®, or C(O)NR’R® ) halogen; : 0X03 : aryl; N aryl substituted by up to three substituents independently selected from lower alkyl, halogen and NR°R® cycloalkyl; oo cycloalkyl substituted by OH, oxo, or NH,,SO.R'¥ and COR"; R® is selected from the group consisting of ~ H; lower alkyl; lower alkyl substituted by NR'R® heterocycle; and . heterocycle substituted by lower alkyl, CO;R” or SOR"; R® is selected from the group consisting of H; and lower alkyl; RI js selected from the group consisting of | . lower alkyl; aryl; and aryl substituted by halogen or NR’R® . ~ : RI! is selected from the group consisting of. oo ; nL Er v. - a. H; lower alkyl; and lower alkyl substituted by oxo or halogen: : g | :-268- oo Ris selected from the group consisting of H; lower alkyl; and lower alkyl substituted by NR’R® or OR"; R'’ and R™ are each independently selected from the group consisting of . H; ’ . lower alkyl; : lower alkyl substituted by CO,R", OR'%, NR’R®, C(O)NR’R?, SOR", NSO.R", . heteroaryl, heterocycle, or heterocycle substituted by oxo; cycloalkyl; a cycloalkyl substituted by CO,R'%, OR", NR°R®, C(O)NR’R® or SOR; aryl; : aryl substituted by NR’R®, OR'2, CO,R'?%, CONR’R’, SOR", halogen, lower alkyl, and lower alkyl substituted by halogen, OR'?, oxo, CO,R"?, C(O)NRR® or NR’R* SO2R'CO.RY; COR; and OR?2 : Rito oO ~~ b AO or alternatively, -NR”’R* can form a ring having 3 to7 ring atoms, said ring optionally including one or more additional N or O ring atoms and optionally being substituted by OH, oxo, NR’R®, lower alkyl and lower alkyl substituted by OR'%; . 20 RY is selected from the group consisting of aryl; ’ aryl substituted by the group halogen, CO,R'?, SOR, COR" , lower alkyl and lower alkyl substituted by halogen, OR'?, oxo, COR", C(O)NR’R® or NR°R; heteroaryl; Co - : Co RE EEEPCT/EP2004/000971 heteroaryl substituted by the group halogen, CORY, SO,RY, COR, lower alkyl and lower alkyl substituted by halogen, OR'?, oxo, CO,R'%, C(O)NR’R® or NR°R%; NRR; lower alkyl; lower alkyl substituted by halogen, OR'?, oxo, CO;R*, C(O)NR’R® or NR°RS; heterocycle, and heterocycle substituted by the group CORY, CORY, SO,R'?, COR"? Jower alkyl, C(O)NR°RSor NR°R®; R!6 and RY are each independently selected from the group consisting of H; and lower alkyl; or, alternatively, the group ~NR'RY can form a ring having 3 to 7 ring atoms, said ring optionally including one or more additional N or O ring atoms and optionally being substituted by lower alkyl, OH, oxo and NH; and n is0, 1 or2; or the pharmaceutically acceptable salts or esters thereof.2. The compound of formula I of claim 1 wherein R! is selected from the group consisting of heterocycle and lower alkyl-heterocycle, wherein the heterocycle moiety in both instances optionally may be substituted by up to four substituents independently selected from H, lower alkyl, lower alkyl substituted by OR'2, COR", NR'R® or C(O)NR’R’, COR’, CORY, COR", C(O)NRPRY, S(O)R", AMENDED SHEET-270 - oo 0X0, OR", or NR°RS; aryl; ‘ aryl substituted by H, -S(0)a-RY, NR’R’, carbonyl, carbonyl substituted by lower alkyl, OR? or NR’RS, lower alkyl, Co lower alkyl substituted by ORY or NR’R®, OR%, or Halogen; cycloalkyl; cycloalkyl substituted by OR’, NR°R® or S(O).R™ lower alkyl; and ~ lower alkyl substituted by - NR’R®, NR''SO;RY,CO.R', S(0)aR", heterocycle, - heterocycle substituted by lower alkyl, COR? or SOR”, heteroaryl, heteroaryl substituted by lower alkyl, CO,R*, or SO,RY,: . aryl, and ) aryl substituted by lower alkyl, halogen, NR°R®, COR", or COR"; R® is selected from the group consisting of ) . BEEN TERA aryl, heteroaryl, cycloalkyl and heterocycle, wherein €ach may be substituted by up: . to four substituents independently selected from the group consisting of-271- So - lower alkyl, _ lower alkyl substituted by halogen or ORY, halogen, ’ ORY? NO,, * CN, : NR’R’, : S(0)n-R’, and :SO.-NR'*RY;10 .,R® and R® are each independently selected from the group consisting of lower alkyl; lower alkyl substituted by COR’, OR'2, NR" R*, C(O)NR"R"*, SOR", : NSO,R'?, heteroaryl, heterocycle, or heterocycle substituted by oxo; cycloalkyl; cycloalkyl substituted by CO,R'?, OR'%, NRPR™ , C(O)NRR* or SO,R'™ aryl; : aryl substituted by NRPR', OR'2, CO,R", C(O)NRPR™, SOR", halogen, lower alkyl, or lower alkyl substituted by halogen, OR'2, oxo, CO,RY, C(O)NRPR" or NRER4SO.R'; . CO:R'% COR" and OR? RM oO ~~ 5 0° ) or alternatively, -NR’R® can form a ring having 3 to.7 ring atoms, said ring optionally including one or more additional N or O ring atoms or the group $0,, arid optionally ; being substituted by OH, oxo, NRPR", lower alkyl and lower alkyl substituted by OR'%;a2 _— Ris selected from the group consisting of H; lower alkyl; , lower alkyl substituted by OR, CO,R'?, NR°R®, or C(O)NR’R® halogen; : 0X0; * aryl; : aryl substituted by up to three substituents independently selected from lower alkyl, halogen and NR’R® cycloalkyl; : cycloalkyl substituted by OH, oxo, or NH,SO.R'* and COR"; R® is selected from the group consisting of . H; lower alkyl; lower alkyl substituted by NERS heterocycle; and - heterocycle substituted by lower alkyl, CO,R22 or SOR? > R? is selected from the group consisting of H; and lower alkyl; RY is selected from the group consisting of . lower alkyl; aryl; and aryl substituted by halogen or NR°R® . : RYis selected from the group consisting of BE ) ] ) } ; a - ia } : ; H; and lower alkyl; oo | - os )-273- CL R'?is selected from the group consisting of H; lower alkyl; and lower alkyl substituted by NRR® or ORY; R'® and RM are each independently selected from the group consisting of i. lower alkyl; | : lower alkyl substituted by CO;R'%, OR'2, NR’R®, C(O)NRR®, SOR”, NSO,R'?, “ heteroaryl, heterocycle, or heterocycle substituted by oxo; cycloalkyl; CL : cycloalkyl substituted by CO,R'2, OR™, NRR®, C(O)NR’R® or SO,R"; aryl; : aryl substituted by NR°R®, OR'?, CO.R'2, CONR’R’, SO,R", halogen, lower alkyl, and lower alkyl substituted by halogen, OR, oxo, CORY, C(O)NR’R® or NR°R® SOR; COR : COR'%; and : OR12 : RO Oo ~ 5 =O or alternatively, -NR'>R"* can form a ring having 3 to7 ring atoms, said ring optionally including one or more additional N or O ring atoms and optionally being substituted by OH, oxo, NR’R®, lower alkyl and lower alkyl substituted by OR"; : 20 RY is selected from the group consisting of aryl; ’ aryl substituted by the group halogen, CORY, SO,R®, COR" , lower alkyl and lower alkyl substituted by halogen, OR", oxo, COR'2, C(O)NR’R® or NR R% heteroaryl; CY ] Lo _ EEE-274- Co heteroaryl substituted by the group halogen, COR", SOR, COR, lower alkyl and lower alkyl substituted by halogen, OR", oxo, COR", C(O)NR’R® or NR°R; NRR; : A lower alkyl; lower alkyl substituted by halogen, OR"? oxo, CORY, C(O)NR’R® or NR°Ré; heterocycle, and heterocycle substituted by the group CO,R'2, COR! 2 SO,R', COR" lower alkyl, C(O)NR’R®or NR°R’; R'® and RY are each independently selected from the group consisting of H and lower alkyl; or, alternatively, the group ~NR'R" can form a ring having 3 to 7 ring atoms, said ring : optionally including one or more additional N or O ring atoms and optionally being substituted by lower alkyl, OH, oxo and NH; and n 1s0,1 or 2; or the pharmaceutically acceptable salts or esters thereof.3. The compound of formula I of claim 1 or claim 2, wherein R? is phenyl.4. The compound of formula I of claim 1 or claim 2, wherein R? is phenyl substituted by halogen or OR'%, and R'? is lower alkyl.5. The compound of formula I of claim 4, wherein the halogen is F and the R"% is methyl.6. The compound of formula I of claim 1, wherein R! is selected from Ge 1 N° Lge | TRE oo (a), EC RE EAN CES275. SE R4 R4 ¢ R* N : \ AN R3 RS RS OR? (d), (e)s 0, R® | R* R# Nel 0) S(O), AN L s RS R6 : (8) R® (h),and <i), wherein R® is selected from the group consisting of H, oe lower alkyl, ] lower alkyl substituted by oxo, OR, COR, NR’R®, SO,R'” or C(O)NR’RS,CO.R’, COR", : : C(O)NR’R’, and SOR"; R* is selected from the group consisting of : : H, lower alkyl, NR’R® ’ NO, RY 0X0 ) CN, and Co N . halogen; E . EE ) RY is selected from the group consisting of ~~ - -.o. oo a. So: ’ PCT/EP2004/000971ORY, lower alkyl, NR°RS, NO, CN, and halogen; R’and R® are each independently selected from the group consisting of H, lower alkyl, lower alkyl substituted by oxo, CO:R'%, OR”, NR" RY, C(O)NRU RM, SOR, NSO,R'?, heteroaryl, heterocycle, or heterocycle substituted by oxo, cycloalkyl, cycloalkyl substituted by CO;R", OR", NRE RM, C(O)NR¥R™ or SO;R”, aryl, aryl substituted by NR¥R™, OR'%, CO,R", C(O)NRVR", SO:R", halogen, lower alkyl, and lower alkyl substituted by halogen, OR'2, oxo, CO;R', C(O)NRPR'* and NRPPRY; SO:RY, COR", COR", and OR12 RYO - | 0 or alternatively, -NR® RS can form a ring having 3 to 7 atoms, said ring optionally including one or more additional N or O atoms and optionally being substituted by OH, oxo, NR"’R'*, lower alky! and lower alkyl} substituted by OR'%; Ris selected from the group consisting of H, lower alkyl, lower alkyl substituted by OR'?, COR, NR°R®, or CONR’RS, halogen, oxo, aryl, aryl substituted by up to three substituents independently selected from lower alkyl, halogen, and NRR®, cycloalkyl, AMENDED SHEET: “277 a cycloalkyl substituted by OH, oxo, or NH,, SOR", and COR; R® is selected from the group consisting of . 5 H, lower alkyl, : lower alkyl substituted by NR°R®, : heterocycle, and heterocycle substituted by lower alkyl, CO,R" or SO,R3; R' isselected from the group consisting of lower alkyl, aryl, and aryl substituted by halogen or NR°RS;.. - R'is selected from the group consisting of H, lower alkyl, and lower alkyl substituted by oxo and halogen; Ris selected from the group consisting of H, lower alkyl, and lower alkyl substituted by halogen, oxo, NR’R® or OR"); R” and R™ are independently selected from the group consisting of H, lower alkyl, lower alkyl substituted by CO,R'%, OR'?, NR°R®, C(O)NR’R’, SOR", NSO,R™2, heteroaryl, heterocycle, or heterocycle substituted by oxo, cycloalkyl, . cycloalkyl substituted by CO,R', OR', NR°R®, C(O)NR®R® or SO,R", aryl, aryl substituted by NR°R®, OR", CO,R', C(O)NRR?, SOR", halogen, lower alkyl, and lower alkyl substituted by halogen, ORY, oxo, CORY, C(O)NR’R® and NR°RS;SO.R", CORY, COR", and OR?2RYO. : or alternatively, -NR"R" can form a ring having 3 to 7 ring ators, said ring optionally, including one or more additional N or O ring atoms and optionally being substituted by - OH, oxo, NR’R’, lower alkyl and lower alkyl substituted by OR'%" . ST-278- oo R™ is selected from the group consisting of oo aryl, aryl substituted by the group halogen, COR, SO,R'?, CORY, lower alkyl and ’ lower alkyl substituted by halogen, OR", oxo, CORY, C(O)NR’R® or NR°R®, heteroaryl, ° : heteroaryl substituted by the group halogen, CO,R", SO,R*®, COR", lower alkyl and lower alkyl substituted by halogen, OR", oxo, CO,R'?, C(O)NR’R® or NR’R’, NRR’, lower alkyl, lower alkyl substituted by the group halogen, OR'?, oxo, CO,R", C(O)NR’R® or * NR°R® : heterocycle, and oo heterocycle substituted by the group COR, CORY, SO,R'2, lower alkyl C(O)NR’R® or NR°RS; X isselected from the group consisting of ‘ S, SO, SO, and O; and n is0, 1 or 2; or the pharmaceutically acceptable salts or esters thereof.7. The compound of formula I of claim 6 having the formula NH, O R21 N ~~ R18 "R20 NS | R HN RIS Cr : I(@), R® wherein R® and R* are as defined in claim 6 and R! RY RY and R* areeach ) independently selected from lower alkyl, halogen and OR. :8. The compound of formiila I(a) of claim 7, wherein R® is selected from the group consisting of COR’, COR"? and SO,R” and R’, R”? and R"® are as defined in claim 6.-279 - a9. The compound of formula I(a) of claim 8, wherein R’,R*? and R*® are hydrogen or lower alkyl. ' 10. The compound of formula I(a) of claim 8, wherein R? is SO,RY and R¥ is lower alkyl or NR’RS. «11. The compound of formula I(a) of claim 7 selected from the group consisting of 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- carboxylic acid ethyl ester, - 4-[4-amino-5-(2,6-difluoro-benzoyl)-pyrimidin-2-ylamino] -piperidine-1- carboxylic acid ethyl ester, 4- [4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2 _ylamino] -piperidine-1- carboxylic acid ethyl ester, . 1-[4- [4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin-1-yl]- ethanone, 1-[4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino} -piperidin-1 -yl}- propan-l-one, oo 1-[4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1 -yl]- butan-1-one, 1-[4- [4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin-1-yl]-3- methyl-butan-1-one, 1-[4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl}-3- diethylamino-propan-1-one, 4-[4-amino-5-(2-methyl-benzoyl)-pyrimidin-2-ylamino]-piperidine-1-carboxylic acid ethyl ester, 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- carboxylic acid methyl ester, ) 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidine-1- carboxylic acid propyl ester, Co RA : 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1: a carboxylic acid iso-butyl ester, Co Ce: PCT/EP2004/0009714-[4-amino-5-(2-methoxy-benzoyl) -pyrimidin-2-ylamino]-piperidine-1- carboxylic acid methylamide, 4- [4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- carboxylic acid ethylamide, 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- carboxylic acid propylamide, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2- methoxy-phenyl)-methanone, [4-amino-2-(1-ethanesulfonyl-piperidin -4-ylarnino)-pyrimidin-5-yl]- (2-methoxy- phenyl)-methanone, [4-amino-2-[1-(propane-1 _sulfonyl)-piperidin-4-ylamino] -pyrimidin-5-y1}-(2- methoxy-phenyl)-methanone, 1-[4- [4-amino-5-(5-fluoro-2-methoxy-benzoyl) -pyrimidin-2-ylamino]-piperidin- 1-yl]-ethanone, 4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidine-1- carboxylic acid methyl ester, 4- (4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidine-1- carboxylic acid propyl ester, 1-[4- [4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin- 1-yl]-propan-1l-one, 1-[4- [4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin- 1-yl]-butan-1-ons, 4-[4-amino-3-(2-methoxy-benzoyl) -pyrimidin-2-ylamino] -piperidine-1- carboxylic acid dimethylamide, [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(3-fluoro- 2-methoxy-phenyl)-methanone, [4-amino-2-(1 ethanesulfonyl-piperidin-4-ylamino)-pyrimidin-3-yll -(5-fluoro-2- methoxy-phenyl)-methanone, AMENDED SHEET-281- oo [4-amino-2-{i-(propane-1-sulfonyl)-piperidin-4-ylamino]-pyrimidin-5-yl]-(5- fluoro-2-methoxy-phenyl)-methanone, : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2-fluoro- phenyl)-methanone, [4-amino-2-(1-ethanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2-fluoro- phenyl)-methanone, 4-[4-amino-5-(2-fluoro-benzoyl)-pyrimidin-2-ylamino}-piperidine-1-carboxylic acid ethyl ester, [4-amino-2-(1-trifluoromethanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}- (5-fluoro-2-methoxy-phenyl)-methanone, - A 4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidine-1- -a. sulfonic acid dimethylamide, 1-{4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino}-piperidin- - .- - 1-yl}-2-dimethylamino-ethanone, AEE co 1-[4-]4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino) -piperidin- : . - : 1-yl]-2-diethylamino-ethanone, En eo 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino) -piperidin- - : 1-y1]-2-morpholin-4-yl-ethanone, . Co ol 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino) -piperidin- " : 20 1-yl]-3-dimethylamino-propan-1-one, Ce 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino}-piperidin- 1-yl]-3-diethylamino-propan-1-one, 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin- 1-yl]-3-piperidin-1-yl-propan-1-one, oo 25 © 1-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin- : 1-y1]-3-morpholin-4-yl-propan-1-one, ’ [4-amino-2-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-ylamino]- Ce hs pyrimidin-5-y1]-(5-fluoro-2-methoxy-phenyl)-methanone. ) K vo N oo282- SE (4: [4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] -piperidin-1- yl]-acetic acid methyl ester, 1-[4- [4-amino-5-(2,6-difluoro-3-methoxy-benzoyl)-pyrimidin-2-ylamino) - piperidin-1-yl}-ethanone, [4-amino-2-( I-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2,6- difluoro-3-methoxy-phenyl)-methanone, 4-[4-amino-5-(2,6-difluoro-3-methoxy-benzoyl)-pyrimidin-2-ylamino]- piperidine-1-carboxylic acid methyl ester, : : 1-[4-[4-amino-5-(2-ethoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1 -yli- : ethanone, - [4-amino-2-[1-(thiophene-3-sulfonyl)-piperidin-4-ylamino] -pyrimidin-5-yl}-(5- fluoro-2-methoxy-phenyl)-methanone, : Co : oo [4-amino-2-[1-(benzo[b] thiophene-3-sulfonyl)-piperidin-4-ylamino]-pyrimidin-- 5-yl}-(5-fluoro-2-methoxy-phenyl)-methanone, Co [4-amino-2-[1-( 1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-ylamino] - pyrimidin-5-yl]-(5-fluoro-2-methoxy-phenyl)-methanone, . - 3-[4- (4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] - : ’ piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester, and CL : : [4-amino-2-[1-(2,5-dimethyl-thiophene-3-sulfonyl)-piperidin-4-ylamino]- pyrimidin-5-yl]-(5-fluoro-2-methoxy-phenyl)-methanone, CL 4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino}-piperidine-1- carboxylic acid cyclohexylamide, 1-[4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino}- piperidin-1-yl]-ethanone, : (4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)- pyrimidin-5-y1]-(2,3- - difluoro-6-methoxy-phenyl)-methanone, ’ [4-amino-2-(piperidin-4-ylamino)-pyrimidin-5-yl]-(2-methoxy-phenyl)- Ce methanone, So — cL Lo . CT-283- oo (4-amino-2- (piperidin-4-ylamino)-pyrimidin-5-yl] -(5-fluoro-2-methoxy-phenyl)- methanone, . [4-amino-2-(piperidin-4-ylamino)-pyrimidin-5-yl]-(2,3-difluoro-6-methoxy- phenyl)-methanone, 1-[4~[4-amino-5-(2,3,4-trifluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]- : piperidin-1-yl]-ethanone, : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl)-(3,4,5- trifluoro-2-methoxy-phenyl)-methanone, : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-y1]-(2,3,4- trifluoro-6-methoxy-phenyl)-methanone, Sons : [4-amino-2-[1-(2-methanesulfonyl-ethyl)-piperidin-4-ylamino] -pyrimidin-5-yl]- (5-fluoro-2-methoxy-phenyl)-methanone, 1-[4-[4-amino-5-(5-fluoro-2-methyl-benzoyl)-pyrimidin-2-ylamino]-piperidin-1- . - yl]-ethanone, : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(5-fluoro- 2-methyl-phenyl)-methanone, So : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(5-fluoro- 2-trifluoromethyl-phenyl)-methanone, Ce [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(5-fluoro- 2-isopropoxy-phenyl)-methanone, (4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-y1] -(2-ethoxy- 5-fluoro-phenyl)-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2-ethyl-5- fluoro-phenyl)-methanone, Co 25 [4-amino-2-(1-methanesulfonyl-piperidin-4-ylaming)-pyrimidin-5-yl}-(2- methoxy-4-trifluoromethyl-phenyl)-methanone, 4-[4-amino-5-(2-fluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]-pipéridine-1- carboxylic acid tert-butyl ester, SE So EL_284- Co [4-amino-2- (piperidin-4-ylamino)-pyrimidin-5-yl] -(2-fluoro-6-methoxy-phenyl)- methanone, [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-y1] -(2-fluoro- 6-methoxy-phenyl)-methanone, 1-[4- [4-amino-5-(2-fluoro-6-methoxy-benzoyl) _pyrimidin-2-ylamino) -piperidin- 1-y1]-2,2,2-trifluoro-ethanone, (4-amino-2-[1-(3-chloro-propane- 1-sulfonyl)-piperidin-4-ylamino] -pyrimidin-5- yl] -(2,3-difluoro-6-methoxy-phenyl)-methanone, (4-amino-2-[1-[3-(2-hydroxy- 1-methyl-ethylamino)-propane-1 -sulfonyl]- : piperidin-4-ylamino]-pyrimidin-5-y1)-(23-difluoro-6-methoxy-phienyl)-methanone, (4-amino-2-[1-[3-(4-methyl-piperazin-1-yl)-propane-1-sulfonyl] -piperidin-4- ylamino)-pyrimidin-5-yl)- (2,3-difluoro-6-methoxy-phenyl)-methanone, (4-amino-2-[1- (3-((R)-1-hydroxymethyl-propylamino)-propane- 1-sulfonyl]- piperidin-4-ylamino] -pyrimidin-5-y1)- (2,3-difluoro-6-methoxy-phenyl) -methanone, _ 15 '4-ammino-2-[1-(3-hydroxy-propane-1-sulfonyl)-piperidin-4-ylamino]-pyrimidin- 5-yl}-(2,3-difluoro-6-methoxy-phenyl)-methanone, [4-amino-2-[1-(3-pyrrolidin- 1-yl-propane-1 _sulfonyl)-piperidin-4-ylamino] - pyrimidin-5-y1}-(2,3-difluoro-6-methoxy-phenyl)-methanone, SL : (4-amino-2-{1 _(3-morpholin-4-yl-propane- 1 _sulfonyl)-piperidin-4-ylamino] - pyrimidin-5-yl]-(2,3-difluoro-6-methoxy-phenyl)-methanone, [4-amino-2-(1-[3-[4- (2-hydroxy-ethyl)-piperazin- 1-yl]-propane-1-sulfonyl]- piperidin-4-ylamino)-pyrimidin-5-yl] - (2,3-difluoro-6-methoxy-phenyl) -methanone, {4-amino-2-(1-[3-[(2-methoxy-cthyl)-methyl-amino]-propane-1-sulfonyl]- piperidin-4-ylamino) -pyrimidin-5-yl] -(2,3-difluoro-6-methoxy-phenyl)-methanone, (4-amino-2-{1-[3-(2-hydroxy-1,1-dimethyl-ethylamino)-propane-1-sulfonyl)- . piperidin-4-ylamino] pyrimidin-5-y1)-(2,3-difluoro-6-methoxy-phenyl) -methanone, (4-amino-2-[1- [3-(2-hydroxy-propylamino)-propane- 1-sulfonyl]-piperidin-4- Jlamino]-pyrismidin-5-yD-(2,3-difluoro-6-methoxy-phenyl-methanonie : NB Lo- 285 - So (4-amino-2-[1-[3-((S)-2-hydroxy- 1-methyl-ethylamino)-propane-1 -sulfonyl]- piperidin-4-ylamino)-pyrimidin-5-yl)-(2,3-difluoro-6-methoxy-phenyl)-methanone, ) (4-amino-2-[1-[3-((R)-1 -hydroxymethyl-2-methyl-propylamino)-propane-1 - sulfonyl] -piperidin-4-ylamino]-pyrimidin-5-yl)-(2,3-difluoro-6-methoxy-phenyl)- : 5 methanone, (4-amino-2-[1-[3-((R)-2-hydroxy-1-methyl-ethylamino)-propane- 1-sulfonyl] - piperidin-4-ylamino]-pyrimidin-5-yl)-(2,3-difluoro-6-methoxy-phenyl)-methanone, (4-amino-2-{1-[3-((S)-1 -hydroxymethyl-propylamino)-propane-1-sulfonyl]- * piperidin-4-ylamino]-pyrimidin-5-yl)- (2,3-difluoro-6-methoxy-phenyl)-methanone,[4-amino-2-(1-[3-[3-hydroxy-1-(2-hydroxy-ethyl)-propylamino]-propane-1- sulfonyl]-piperidin-4-ylamino)-pyrimidin-5-yl}-(2,3-difluoro-6-methoxy-phenyl)- methanone,~~ [4-amino-2-[ 1-(3-chloro-propane-1-sulfonyl)-piperidin-4-ylamino] -pyrimidin-5- yl] -( 5-fluoro-2-methoxy-phenyl)-methanone, :[4-amino-2-(1-[3-[ (2-methoxy-ethyl)-methyl-amino]-propane-1-sulfonyl}- : piperidin-4-ylamino)-pyrimidin-5-y1}-(5-fluoro-2-methoxy-phenyl)-methanone,[4-amino-2-(1-(3-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-propane-1-sulfonyl]- piperidin-4-ylamino)-pyrimidin-5-yl] -(5-fluoro-2-methoxy-phenyl) -methanone, (4-amino-2-[1-[3-((S)-2-hydroxy-1-methyl-ethylamino)-propane-1 -sulfonyl}- piperidin-4-ylamino}-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone, (4-amino-2-[1-[3-((R)-1-hydroxymethyl-propylamino)-propane-1-sulfonyl]- piperidin-4-ylamino] -pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone, (4-amino-2-[1-[3-(2-hydroxy-propylamino)-propane-1-sulfonyl]-piperidin-4- ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone, (4-amino-2-{1-[3-((R)-1-hydroxymethyl-2-methyl-propylamino)-propane-1- sulfonyl] -piperidin-4-ylamino]-pyrimidin-5-yl)- (5-fluoro-2-methoxy-phenyl)- : methanone, (4-amino-2-[1-3-(2-methoxy- 1-methyl-ethylamino)-propane-1 -sulfonyl]- - - . piperidin-4-ylamino]-pyrimidin-5-yl) -(5-fluoro-2-methoxy-phenyl) -metharione, Co-286- a (4-amino-2-[1-[3-(2-hydroxy-1 ,1-dimethyl-ethylamino)-propane-1-sulfonyl] - piperidin-4-ylamino]-pyrimidin-5-y1)-(5-fluoro-2-methoxy-phenyl)-methanone, (4-amino-2-[1-[3-((R)-2-hydroxy-1-methyl-ethylamino)-propane-1-sulfonyl]- piperidin-4-ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone, (4-amino-2-[1-[3-((S)-1-hydroxymethyl-propylamino)-propane-1-sulfonyl}- piperidin-4-ylamino]-pyrimidin-5-y1)-(5-fluoro-2-methoxy-phenyl)-methanone, [4-amino-2-[1-(4-hydroxy-butane-1-sulfonyl)-piperidin-4-ylamino} -pyrimidin-5- yl]-(5-fluoro-2-methoxy-phenyl)-methanone, [4-amino-2-[1-(4-chloro-butane-1-sulfonyl)-piperidin-4-ylamino]-pyrimidin-5- yl]-(5-fluoro-2-methoxy-phenyl)-methanone, Sod ' (4-amino-2-[1-[4-(4-methyl-piperazin-1-yl)-butane-1-sulfonyl] -piperidin-4- ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone, : [4-amino-2-[1-(4-pyrrolidin-1-yl-butane- 1-sulfonyl)-piperidin-4-ylamino}- pyrimidin-5-yl]-(5-fluoro-2-methoxy-phenyl)-methanone, : (4-amino-2-[1- [4-(2-hydroxy-propylamino)-butane- 1-sulfonyl]-piperidin-4- ylamino]-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone, [4-amino-2-(1 _methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2,3- ~ difluoro-5,6-dimethoxy-phenyl)-methanone, Co [4-amino-2-(1 _methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2,3- difluoro-6-hydroxy-5-methoxy-phenyl)-methanone, (4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl} -(2,3- difluoro-5,6-dihydroxy-phenyl)-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(2,3- difluoro-5-hydroxy-6-methoxy-phenyl)-methanone, Co 25 © [4-amino-2-[1-(3-chloro-propane-1-sulfonyl)-piperidin-4-ylamino] -pyrimidin-5- y1]-(5-fluoro-2-methoxy-phenyl)-methanone, ’ ~ [4-amino-2-[1-(3-pyrrolidin-1-yl-propane-1 -sulfonyl)-piperidin-4-ylamiho}- - pyrimidin-5-y1]-(5-fluoro-2-methoxy-phenyl)-methanone, . B v Lo287 - Co acetic acid 3-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]- piperidine-1-sulfonyl]-propyl ester, _ [4-amino-2-[1-(3-hydroxy-propane-1-sulfonyl)-piperidin-4-ylamino}-pyrimidin- 5-yl]-(5-fluoro-2-methoxy-phenyl)-methanone, [4-amino-2-[1-(3-morpholin-4-yl-propane-1 -sulfonyl)-piperidin-4-ylamino] - pyrimidin-5-y1]-(5-fluoro-2-methoxy-phenyl)-methanone, N-(3-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]- piperidine-1-sulfonyl]-propyl)-methanesulfonamide, ) (4-amino-2-[1-[3-(4-methyl-piperazin-1-yl)-propane- 1-sulfonyl] -piperidin-4- ylamino)-pyrimidin-5-y1)-(5-fluoro-2-methoxy-phenyl)-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-y1]-(2,3- difluoro-6-hydroxy-phenyl)-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -phenyl- methanone, 4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]- piperidine-1-carbaldehyde, - 4- [4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino] - piperidine-1-sulfonic acid amide, : : . 4- [4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]- piperidine-1-sulfonic acid acetyl-amide, rac-[4-amino-2-(3-hydroxy-1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin- 5-y1)-(2,3-difluoro-6-methoxy-phenyl)-methanone, rac-[4-amino-2-(3-hydroxy-1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin- 5-y1]-(2,3-difluoro-6-methoxy-phenyl)-methanone, Co 25 . rac-[4-amino-2-(1-methanesulfonyl-3-methoxy-piperidin-4-ylamino)-pyrimidin- } 5-yl]-(2,3-difluoro-6-methoxy-phenyl)-methanone, rac-4-[4-amino-5- (2,3-difluoro-6-methoxy-benzoyl) -pyrimidin-2-ylamirfo] -1- methanesulfonyl-piperidin-3-one, Co I-288- S 1-[4-[4-amino-5-(2-methoxy-5-methyl-benzoyl)-pyrimidin-2-ylamino] _piperidin- 1-yl]-ethanone, : ’ [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(2- methoxy-5-methyl-phenyl)-methanone, (4-amino-2-ethylsulfanyl-pyrimidin-5-y1)-(2,5-dimethoxy-phenyl)-methanone, 1-{4-[4-amino-5-(2,5-dimethoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1 -yl}- ethanone, » [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2,5- dimethoxy-phenyl)-methanone, : 1-[4-[4-amino-5-(2,6-dimethoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1 -yl]- ethanone, [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin- 5-y1}-(2,6- dimethoxy-phenyl)-methanone, : 1-[4- [4-amino-5-(5-fluoro-2-methoxy-4-methyl-benzoyl)-pyrimidin-2-ylamino] - piperidin-1-yl]-ethanone, [4-amino-2-(1 -methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(5-fluoro- 2-methoxy-4-methyl-phenyl)-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(3-fluoro- 2,6-dimethoxy-phenyl)-methanone, [4-amino-2-(1 —methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2-ethoxy- 3-fluoro-6-methoxy-phenyl)-methanone, 1-[4- [4-amino-5-(3-fluoro-6-methosy-2-methyl-benzoyl)-pyrimidin-2-ylamino} - ~ piperidin-1-yl]-ethanone, . [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(3-fluoro- 6-methoxy-2-methyl-phenyl)-methanone, 1-[4-[4-amino-5-(4-methyl-benzoyl)-pyrimidin-2-ylamino] -piperidin-1-yl]- ethanone, oo Co : _ - IR {4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrirhidin-5-ylJ:p-tolyl- . methanone, . oo ] EEE oo -280- oo 1-[4-[4-amino-5- (4-methoxyl-benzoyl)-pyrimidin-2-ylamino]-piperidin-1 yl] ethanone, : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(4- methoxy-phenyl)-methanone, 1-[4~[4-amino-5-(4-chloro-benzoyl)-pyrimidin-2-ylamino] -piperidin-1-yl]- ethanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-y1]-(4-chloro- _ phenyl)-methanone, 1-[4~(4-amino-5-(4-fluoro-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-y1]- : ethanone, -e [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(4-fluoro- phenyl)-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(5-fluoro- 2,4-dimethoxy-phenyl)-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(4-ethoxy- 5-fluoro-2-methoxy-phenyl)-methanone, [4-Amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(3-fluoro- 4-methoxy-phenyl)-methanone, 4-[4-amino-5-(5-fluoro-2-methoxy-4-methyl-benzoyl)-pyrimidin-2-ylamino]- piperidine-1-carboxylic acid tert-butyl ester, (4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -(4-chloro- 5-fluoro-2-methoxy-phenyl)-methanone, : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(3,5- difluoro-2-methoxy-phenyl)-methanone, Co 25 : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(2-fluoro- 5-methoxy-4-methyl-phenyl)-methanone, and ; - [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl] -( 5-fluoro- 2-methoxy-3-methyl-phenyl)-methanone. = | So cL B cL CL . - ol-290- a12. The compound of formula I of claim 6 having the formula : NH, O R21 : NZ R18 20 , N | R : HN R19 RA4 i(e), N : RN RS R6 FRET wherein R%, R®, RS, R'8, RY, R?® and R*! are as defined in claim 6."13. The compound of formula I(e) of claim 12, wherein R*%, R'’, R? and R* are each independently selected from lower alkyl, halogen and OR? and R"?is hydrogen or lower alkyl.14. The compound of formula I(e) of claim 12, wherein R® and R® are independently selected from H, COR" and SO,R*® and R*? and R"” are hydrogen or lower alkyl.15. The compound of formula I(e) of claim 12 selected from the group consisting - of: trans-[4- [4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] - cyclohexyl]-carbamic acid tert-butyl ester, B trans-|4-amino-2-(4-amino-cyclohexylamino)-pyrimidin-5-yl]-(5-fluoro-2- methoxy-phenyl)-methanone, trans-N-[4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino}- cyclohexyl] -acetamide, : N-[4-[4-amino-5-( 5-fluoro-2-methoxy-benzoyl-pyrimidin-2-ylamino] - cyclohexyl]-methanesulfonamide, . Co : ethanesulfonic acid [4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2- ylamino]-cyclohexyl]-amide, : EE SE FO-291- SI (4-{4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino] cyclohexyl] - carbamic acid ethyl] ester, : [4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-cyclohexyl]- carbamic acid isopropyl ester, [4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-cyclohexyl}- carbamic acid 2-methoxy-ethyl ester, trans- N-[4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]- cyclohexyl]-acetamide, trans- N-[4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]- cyclohexyl]-methanesulfonamide, So trans-[4-amino-2-[4-(2-hydroxy-ethylamino)-cyclohexylamino]-pyrimidin-5-yl} - (2,3-difluoro-6-methoxy-phenyl)-methanone, trans-(4-amino-2-(4-[bis-(2-hydroxy-ethyl)-amino}-cyclohexylamino]-pyrimidin- 5-y1)-(2,3-difluoro-6-methoxy-phenyl)-methanone, trans-N-[4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]- cyclohexyl ]-succinamic acid, - trans-3-chloro-propane-1-sulfonic acid [4- [4-amino-5-(2,3-difluoro-6-methoxy- benzoyl)-pyrimidin-2-ylamino]-cyclohexyl]-amide, : trans-3-morpholin-4-yl-propane-1-sulfonic acid [4-[4-amino-5-(2,3-difluoro-6- methoxy-benzoyl)-pyrimidin-2-ylamino]-cyclohexyl}-amide, trans-3-(4-methyl-piperazin-1-yl)-propane-1-sulfonic acid [4-[4-amino-5-(2,3- difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]-cyclohexyl]-amide, trans-3-pyrrolidin-1-yl-propane-1-sulfonic acid [4-[4-amino-5-(2,3-difluoro-6- methoxy-benzoyl)-pyrimidin-2-ylamino}-cyclohexyl]-amide, © trans-3-hydroxy-propane-1-sulfonic acid [4-[4-amino-5-(2,3-difluoro-6-methoxy- benzoyl)-pyrimidin-2-ylamino]-cyclohexyl]-amide, trans- (4-amino-2-(4-(1,1-dioxo-11’-isothiazolidin-2-yl)-cyclohexylamino]- - pyrimidin-5-yl]-(2,3-difluoro-6-methoxy-phenyl)-methanone, [EE-202- Co ~ trans-[4-amino-2-[4-(4-methyl-piperazin- 1-yl)-cyclohexylamino]-pyrimidin-5- y1]-(2,3-difluoro-6-methoxy-phenyl)-methanone,. : trans-[4-amino-2-(4-pyrrolidin-1-yl-cyclohexylamino)-pyrimidin-5-yl] -(2,3- difluoro-6-methoxy-phenyl)-methanone, trans-{4-amino-2- (4-dimethylamino-cyclohexylamino)-pyrimidin-5-yl] -(2,3- difluoro-6-methoxy-phenyl)-methanone, [4-[4-amino-5-(2-methoxy-5-methyl-benzoyl)-pyrimidin-2-ylamino]-cyclohexyl]- carbamic acid tert-butyl ester, [4-amino-2-(4-amino-cyclohexylamino)-pyrimidin-5-yl]-(2-methoxy-5-methyl- phenyl)-methanone, EE N-[4-[4-amino-5-(2-methoxy-5-methyl-benzoyl)-pyrimidin-2-ylamino]- cyclohexyl] -acetamide, N-[4-[4-amino-5-(2-methoxy-5-methyl-benzoyl)-pyrimidin-2-ylamino]- cyclohexyl]-methanesulfonamide, [4-[4-amino-5-(5-fluoro-2-methoxy-4-methyl-benzoyl)-pyrimidin-2-ylamino}- cyclohexyl]-carbamic acid tert-butyl ester, [4-amino-2-(4-amino-cyclohexylamino) _pyrimidin-5-yl] -(5-fluoro-2-methoxy-4- methyl-phenyl)-methanone, N-[4- [4-amino-5-(5-fluoro-2-methoxy-4-methyl-benzoyl)-pyrimidin-2-ylamino] - cyclohexyl]-acetamide, and N-[4-[4-amino-5-(5-fluoro-2-methoxy-4-methyl-benzoyl)-pyrimidin-2-ylamino]- cyclohexyl]-methanesulfonamide.16. The compound of formula I of claim 6 having the formula NH, O R21 : N= R18 20 ' PN | R HN R19 R# (9), N ON RS RS 7 wherein RY, R%, R®, R'%, R'’, R? and R* are as defined in claim 6."17. The compound of formula I(g) of claim 16, wherein R'8, RY, R® and R* are each independently selected from lower alkyl, halogen and OR".18. The compound of formula I(g) of claim 16, wherein R* is selected from the group consisting of H, OR"! and lower alkyl and R'is hydrogen or lower alkyl.19. The compound of formula I(g) of claim 16, wherein NRR® forms a ring having 3 to 7 ring atoms, said ring optionally including one or more additional N or O ring atoms and optionally being substituted by OH, oxo, NHy, lower alkyl and lower alkyl substituted by OR" and R* is hydrogen or lower alkyl.20. The compound of formula I(g) of claim 16 selected from the group consisting of: B [4-amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-yl}-(3-15. fluoro-phenyl)-methanone, [4-amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-yl}-(2- to methoxyphenyl)-methanone, : . [4-amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-yl]-(2,6- difluoro-phenyl)-methanone, ~ _ - : [4-amino-2-[4- (4-isopropyl-piperazin-1-y1)-phenylamino] -pyrimidin-5-y1] -(2- methoxy-phenyl)-methanone, CT } So So[4-amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino)-pyrimidin-5-y]-(2,6- difluoro-phenyl)-methanone, . [4-amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-y1]-(5- fluoro-2-methoxy-phenyl)-methanone, ] 5 [4-amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-yl]-(5- fluoro-2-methoxy-phenyl)-methanone, [4-amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-yl}-o-tolyl- methanone, ’ [4-amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-yl}-o- tolyl-methanone, and ES 4-[4-amino-5-(5-fluoro-2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1- carboxylic acid (4-dimethylamino-phenyl)-amide.21. A compound of formula I of claim 1, selected from the group [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]- (5-fluoro- 2-methoxy-phenyl)-methanone, y : trans-N-[4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]- cyclohexyl]-methanesulfonamide, trans-N-[4-{4-amino-5-(5-fluoro-2-methoxy-benzoyl-pyrimidin-2-ylamino]- cyclohexyl]-methanesulfonamide, : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2- methoxy-phenyl)-methanone, : : 1-[4-[4-amino-5-(5-fluoro-2-methoixy-benzoyl)-pyrimidin-2-ylamino] -piperidin- 1-yl]-ethanone, . ~ 1-[4-[4-amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino}- piperidin-1-yl]-ethanone and j . trans- N-[4-[4-Amino-5-(2,3-difluoro-6-methoxy-benzoyl)-pyrimidin-2- . : ylamino]-cyclohexyl] -acetamide. oo ) So Co- 295 - Co22. A compound of formula I of claim 1, whichis 1-[4-[4-amino-5-(5-fluoro-2- methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidin-1-yl]-ethanone.23. A compound of formula I of claim 1, which is [4-amino-2-(1-methanesulfonyl- . piperidin-4-ylamino)-pyrimidin-5-yl]-(5-fluoro-2-methoxy-phenyl)-methanone.24. A compound of formula I of claim 1, which is [4-amino-2-(1-methanesulfonyl- piperidin-4-ylamino)-pyrimidin-5-yl}-(2,3-difluoro-6-methoxy-phenyl)-methanone. “ 25. A compound of formula I of claim 1, which is trans- N-[4-[4-amino-5-(2,3- difluoro-6-methoxy-benzoyl)-pyrimidin-2-ylamino]-cyclohexyl] -methanesulfonamide.26. A compound of formula I of claim 1, which is 4-[4-amino-5-(2,3-difluoro-6- methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1-sulfonic acid amide.27. A compound of formula I of claim 1, selected from the group [4-amino-2-(4-amino-cyclohexylamino)-pyrimidin-5-yl] -(2,3-difluoro-6- methoxy-phenyl)-methanone, . : (4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2,3 »4- trifluoro-6-methoxy-phenyl)-methanone, : [4-amino-2-( 1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2-fluoro- 6-methoxy-phenyl)-methanone, : {4-amino-2-{1-(3-pyrrolidin-1-yl-propane-1-sulfonyl)-piperidin-4-ylamino|- pyrimidin-5-yl}-(5-fluoro-2-methoxy-phenyl)-methanone, (4-amino-2-{1-[3-(4-methyl-piperazin-1-yl)-propane- 1-sulfonyl]-piperidin-4- ylamino}-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl}-(5-fluoro- 2-methoxy-4-methyl-phenyl)-methanone, . [4-amino-2-[1-(3-chloro-propane-1 -sulfonyl) -piperidin-4-ylamino] -pyrimidin-5- : yl]-(2,3-difluoro-6-methoxy-phenyl)-methanone, - Se Co {4-amino-2-[ 1-(3-pyrrolidin-1-yl-propane-1-sulfonl)-piperidin-4-ylamino} - : pyrimidin-5-y1}-(2,3-difluoro-6-methoxy-pheny})-methanone, oo{4-amino-2-[1 -(3-morpholin-4-yl-propane-1-sulfonyl)-piperidin-4-ylamino] - pyrimidin-5-yl}-(2,3-difluoro-6-methoxy-phenyl)-methanone, . [4-amino-2-(1-{3-[4-(2-hydroxy-ethyl) -piperazin-1-yl]-propane-1-sulfonyl}- piperidin-4-ylaminé)-pyrimidin-5-yl]-(2,3-difluoro-6-methoxy-phenyl)-methanone, [4-amino-2-(1-{3-[(2-methoxy-ethyl)-methyl-amino] -propane- 1-sulfonyl}- piperidin-4-ylamino)-pyrimidin-5-yl}- (2,3-difluoro-6-methoxy-phenyl)-methanone, 1-[4-[4-amino-5-(3-methoxy-pyridine-2-carbonyl)-pyrimidin-2-ylamino]- piperidin-1-yl]-ethanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(3- methoxy-pyridin-2-yl)-methanone, 1-[4-[4-amino-5-(3-methyl-thiophene-2-carbonyl)-pyrimidin-2-ylamino]- piperidin-1-yl]-ethanone, : [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(3-methyl- thiophen-2-yl)-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-thiophen- 2-yl-methanone, [4-amino-2-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-5-yl]-(2,3- difluoro-6-hydroxy-phenyl)-methanone, [4-amino-2-(azetidin-3-ylamino)-pyrimidin-5-y1]-(2,3-difluoro-6-methoxy- phenyl)-methanone, [4-amino-2-(1-methanesulfonyl-azetidin-3-ylamino)-pyrimidin-5-yl]-(2,3- difluoro-6-methoxy-phenyl)-methanone, [4-amino-2-(1-ethanesulfonyl-azetidin-3-ylamino)-pyrimidin-5-yl}-(2,3-difluoro- 6-methozy-phenyl)-methanone, and ) 25 ~ [4-amino-2-[ 1-(propane-2-sulfonyl)-azetidin-3-ylamino)] -pyrimidin-5-y}-(2,3- difluoro-6-methoxy-phenyl)-methanone. ’28. A pharmaceutical composition comprising as an active ingredient an effective amount of a compound of any one of claims 1 to 27 and a pharmaceutically acceptable carrier or excipient. Co SE EE-297- SE Co 29. The pharmaceutical composition of claim 28 which is suitable for parenteral administration. : : 30. The pharmaceutical composition of claim 28, wherein the compound is suitable for administration to a patient having cancer.31. Compounds of any one of claims 1 to 27 for use as medicaments.32. Use of compounds of any one of claims 1 to 27 for the preparation of medicaments for the treatment and control of cancer. - 33. The use of claim 32 for treating a solid breast or colon tumor.34. A process for the preparation of a compound of formula I of claim 1, which process comprises reacting a compound of the formula (9) ! N<__-NH RY Ve ~ 2 YY | . Nx 0 rR? | : wherein R* is lower alkyl or benzyl, nis 1 or 2 and R?is as defined in claim 1, with an amine of formula . : s H,N—R In wherein R! is as defined in claim 1, to obtain a compound of the formula MH, O NT R2 PS “= Co | Hn N; . : R CL and if desired, converting the compound of formula I into a pharmaceutically acceptable salt. BE oe BRR IPCT/EP2004/00097135. A compound of formula I of any one of claims 1 to 27 prepared by a process according to claim 34.36. An intermediate compound selected from the group consisting of: 4-amino-2-methylsulfanyl-pyrimidine-5-carboxylic acid methoxy-methyl- amide, 4-amino-2-ethylsulfanyl-pyrimidine-5-carboxylic acid methoxy-methyl- amide, (4-amino-2-ethylsulfanylpyrimidin-5-yl)-(2-methoxy-phenyl)-methanone, (4-amino-2-ethylsulfanyl-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)- methanone, (4-amino-2-ethanesulfinyl-pyrimidin-5-yl)-(5-fluoro-2-methoxy-phenyl)- methanone, (4-amino-2-ethanesulfonyl-pyrimidin-5-y1)-(5-fluoro-2-methoxy-phenyl)- methanone, (4-amino-2-ethylsulfanyl-pyrimidin-5-yl)-(2,3-difluoro-6-methoxy-phenyl)- methanone, and trans-ethanesulfonic acid (4-aminocyclohexyl)-amide, HCI Salt.37. A substance or composition for use in a method for the treatment and control of cancer, said substance or composition comprising compounds of any one of claims 1 to 27, and said method comprising administering said substance or composition.38. A substance or composition for use in a method of treatment of claim 37 for treating a solid breast or colon tumor.39. A compound of any one of claims 1 to 27, 31, 35 or 36, substantially as herein described and illustrated. AMENDED SHEETPCT/EP2004/000971 C - 299 -40. A composition of any one of claims 28 to 30, substantially as herein described and illustrated.41. Use of claim 32 or claim 33, substantially as herein described and illustrated.42. A process of claim 34, substantially as herein described and illustrated.43. A substance or composition for use in a method of treatment of claim 37 or claim 38, substantially as herein described and illustrated. 44, A new compound, a new composition, a new use of a compound of any one of claims 1 to 27, a new process for preparing a compound, or a substance or composition for a new use in a method of treatment, substantially as herein described.45. The novel compounds, pharmaceutical compositions, processes, and uses as described herein before. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44627303P | 2003-02-10 | 2003-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200505564B true ZA200505564B (en) | 2007-01-31 |
Family
ID=38808947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200505564A ZA200505564B (en) | 2003-02-10 | 2005-07-11 | 4-aminopyrimidine-5-one |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101044121A (en) |
CO (1) | CO5590920A2 (en) |
ZA (1) | ZA200505564B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6002223B2 (en) * | 2011-08-26 | 2016-10-05 | ニューファーマ, インコーポレイテッド | Specific chemical entities, compositions and methods |
CN108299312B (en) * | 2018-03-29 | 2020-10-30 | 郑州大学第一附属医院 | Pyrimidine derivatives and application thereof in preparation of antitumor drugs |
WO2022166793A1 (en) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | Cdk inhibitor |
-
2004
- 2004-02-03 CN CN 200480003929 patent/CN101044121A/en active Pending
-
2005
- 2005-07-11 ZA ZA200505564A patent/ZA200505564B/en unknown
- 2005-07-18 CO CO05070756A patent/CO5590920A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101044121A (en) | 2007-09-26 |
CO5590920A2 (en) | 2005-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sana et al. | Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect | |
JP4291135B2 (en) | CDK-inhibiting pyrimidines, their manufacture and use as pharmaceuticals | |
RU2299201C2 (en) | Derivatives of pyrimidine, method for their preparing (variants), pharmaceutical compositions (variants) and inhibition method | |
RU2412186C2 (en) | Pyrazolepyrimidines | |
Wang et al. | Cyclin dependent kinase 1 inhibitors: a review of recent progress | |
CN102143953B (en) | Pyrimidines, triazines and their use as pharmaceutical agents | |
US20060241297A1 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
US20080167330A1 (en) | Carbamoylsulphoximides as protein kinase inhibitors | |
US7705009B2 (en) | 4-aminopyrimidine-5-thione derivatives | |
BR112017003312B1 (en) | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | |
EP1648875A1 (en) | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
DE10349423A1 (en) | Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments | |
US8772280B2 (en) | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as MPS1 kinase inhibitors | |
JP2008535807A (en) | N-aryl-sulfoximine-substituted pyrimidines as CDK- and / or VEGF inhibitors, their production and use as pharmaceutical agents | |
CN108368060B (en) | Pyrimidine derivative kinase inhibitors | |
KR100717099B1 (en) | 4-aminopyrimidine-5-one | |
Fanta et al. | 2-Anilino-4-(1-methyl-1H-pyrazol-4-yl) pyrimidine-derived CDK2 inhibitors as anticancer agents: Design, synthesis & evaluation | |
ZA200505564B (en) | 4-aminopyrimidine-5-one | |
Kizhakkedath Ratheesh et al. | Pyrimidine derivatives as EGFR tyrosine kinase inhibitors in non‐small‐cell lung cancer: A comprehensive review | |
US7423051B2 (en) | 2,6-diaminopyridine derivatives | |
CN1976910B (en) | Novel 2,4-diaminothiazol-5-one derivatives | |
AU2017444054B2 (en) | Class of pyrimidine derivative kinase inhibitors | |
CN1898237B (en) | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | |
BR112019009432A2 (en) | pyrimidine or pharmaceutically acceptable salt compounds, method of preparation thereof, and pharmaceutical composition and healthy functional food | |
KR100839394B1 (en) | Pyrazolo pyrimidines |